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ABSTRACT 
Cleft palate is one of the most common congenital malformations in 
humans which occurs at a frequency of approximately 1:700 live births 
worldwide. Sine Oculis-related homeobox 2 (Six2) is a member of the 
vertebrate Six gene family that encode proteins that are transcription factors. 
Six2 has been reported to be a downstream target of Homeobox a2 (Hoxa2), a 
gene that plays a direct a role in mouse secondary palate (SP) development.  
In my thesis, I utilized quantitative real time Polymerase Chain Reaction 
(qPCR), Western blot analysis and fluorescence immunohistochemisrty  (IHC) 
to characterize the spatial and temporal distribution patterns of Six2 in the 
developing SP. Additionally, I also employed in vivo cell counting analysis and 
in vitro cell proliferation assays to investigate the role of Six2 during palate 
mesenchymal cell proliferation.  
My study examined the temporal and spatial distribution of Six2 in the 
developing mouse palatal mesenchyme and epithelia in both wild-type and 
Hoxa2 null mice.  Six2 was expressed throughout the period of embryonic  
palatogenesis, with the highest levels of Six2 mRNA and protein observed in 
palatal shelves at E13.5 in both wild-type and Hoxa2 null mice. Six2 protein 
expression at all stages of SP development (E12.5 to E15.5) increased in the 
anterior to posterior (A-P) direction with highest expression in the posterior 
regions of the developing SP. In addition, expression of Six2 protein was higher 
in the oral half of the palatal mesenchyme compared to the nasal half of the 
palatal mesenchyme.  Interestingly, Six2 protein was expressed in the nasal 
palatal epithelium but was completely absent from the oral palatal epithelium. 
Loss of the Hoxa2 gene induced up regulation of Six2 protein and mRNA in the 
developing palate across all stages of palatogenesis. In the Hoxa2 null mice, 
there was a significant increase in cell proliferation (Ki-67 positive cells) and 
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the percentage of actively proliferating cells that were co-expressing Six2 
protein (Six2/Ki-67 double positive cells) along both the A-P and oral-nasal (O-
N) axes of the developing SP. Also, the highest percentage of actively 
proliferating cells and Six2/Ki-67 double positive cells was observed in the 
nasal half of the posterior palatal mesenchyme. Furthermore, Six2 siRNA knock 
down in mouse embryonic palatal mesenchyme (MEPM) cell cultures restored  
cell proliferation and Cyclin D1 expression in the Hoxa2 null cell cultures to 
wild-type levels.  
Collectively, my data reveals a novel spatial and temporal expression 
profile for Six2 in the developing mouse SP and the potential role it might play 
during the epithelial-mesenchymal cross talk that drives palatal shelf cell 
proliferation and out growth. 
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1. INTRODUCTION 
Cleft palate is one of the most common congenital malformations in 
humans, occuring at a frequency of approximately 1:700 live births worldwide 
(Gorlin et al., 2001). The palate separates the nasal and oral cavities and this 
allows for respiration, feeding and phonation to occur. Environmental and 
genetic factors have both been implicated in the pathogenesis of the cleft 
palate. Maternal use of the anticonvulsant drugs valproic acid and phenytoin, 
has been shown to cause cleft palate in the newborn (Holmes et al., 2001). 
However, the molecular mechanisms involved in this drug-induced 
manifestation are poorly understood.  
Craniofacial development is a tightly regulated process that involves the 
growth and fusion of the maxillary, mandibular and nasal processes (Chai and 
Maxson, 2006). Mouse secondary palate development begins around E11.5. At 
E12.0-13.5, paired palatal shelves initiate from the oral side of the maxillary 
processes and grow vertically downwards on either side of the tongue. The 
tongue depresses at E14.0 causing the palatal shelves to reorient above the 
tongue. These then grow horizontally towards each other ultimately touching 
at E14.5 to form the midline epithelial seam (MES). The MES degrades by 
E15.5, leaving behind a confluent secondary palate. In addition, the secondary 
palate fuses anteriorly with the primary palate, a derivative of the medial nasal 
processes, to form the intact roof of the oral cavity. Therefore, disruption of 
the growth, elevation or fusion of the palatal shelves can lead to cleft palate 
(Bush and Jiang, 2012; Ferguson, 1988; Gritli-Linde, 2007, Smith et al., 2013). 
Six2 is a member of the vertebrate gene family consisting of the 
following genes: Six1, Six3, Six4, Six5 and Six6 which encode transcription 
factor proteins homologous to the Drosophila 'sine oculis' homeobox protein 
(Kiyoshi et al., 2000). Six2 has been shown to be involved in regulating 
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craniofacial and kidney development (Fogelgren et al., 2008, 2009; Lozanoff, 
1993; Lozanoff et al., 2001; Ma and Lozanoff, 1996, 1999; McBratney et al., 
2003; Singh et al., 1998). Six2 expression has been reported in the 
mesenchyme of the nasal prominences of E11.5 mice (Brodbeck et al., 2004; 
Fogelgren et al., 2008; Ohto et al., 1998; Oliver et al., 1995). Six2 has also been 
reported to be a direct downstream target of Hoxa2 in the murine branchial 
arches (Kutejova et al., 2005; Kutejova et al., 2008).  
Although Six2 has been reported to be expressed during mammalian 
craniofacial development, no detailed expression analysis has been performed 
in the developing secondary palate. In addition, its precise role in the 
craniofacial region and especially in the developing mammalian secondary 
palate is still unknown. My thesis therefore seeks to address these gaps in 
knowledge regarding the transcription factor Six2 during palatogenesis. 
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2. REVIEW OF LITERATURE 
2.1 An overview of craniofacial development 
2.1.1 Early embryonic development 
 In the human embryo, oral development starts early by the appearance 
of the prechordal plate in the bilaminar germ disc on the 14th day of 
development. The endodermal thickening of the prechordal plate demarcates 
the cranial pole of the oval embryonic disk, which later contributes to the 
oropharyngeal membrane. This bilaminar membrane is the site of the junction 
of the ectoderm that forms the mucosa of the mouth and the endoderm that 
forms the mucosa of the pharynx, which is the most cranial part of the foregut. 
The oropharyngeal membrane is one of two sites of contact between 
ectoderm and endoderm, where mesoderm fails to intervene between the two 
primary germ layers; the other site is the cloacal membrane at the terminal 
end of the hindgut. The oropharyngeal membrane also demarcates the 
stomodeum, the primitive mouth that forms the center of the developing face 
(Richman et al., 1995; Sulik et al., 1990). 
 The development of the head relies on the inductive activities of the 
prosencephalic and rhombencephalic organizing centres that are regulated by 
sonic hedgehog (Shh) (Hu et al., 1999) (Fig. 1). Located at the rostral end of the 
notochord beneath the forebrain (prosencephalon) is the prosencephalic 
centre which is derived from the prechordal mesoderm that migrates from the 
primitive streak. This centre induces the visual and inner-ear apparatus and the 
upper third of the face through Shh protein signalling. Similar to the 
prosencephalic centre, the caudal rhombencephalic centre located beneath 
the hindbrain (Rhombencephalon) also induces the middle and lower thirds of 
the face including the middle and external ears through Shh signalling. In 
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association with these developments is the bifurcation of the unilobar 
forebrain (prosencephalon) to form paired telencephalic hemispheres and 
evagination of the paired olfactory bulbs and optic nerves. Failure of these 
cerebral divisions leads to severe facial anomalies (Johnson et al., 1995). 
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Figure 1: A schematic illustration of showing the three primary brain vesicles of 
an early embryo (prosencephalon, mesencephalon and rhombencephalon) and 
their five main subdivisions. 
 (http://what-when-how.com/neuroscience/development-of-the-nervous-
system-gross-anatomy-of-the-brain-part-1/. Web. 0ctober 4th 2014). 
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2.1.2 Migration of the cranial neural crest cell population 
Formation of cranial neural crest cells (CNCC) is one of the key features 
of craniofacial development. The specification, emigration and migration, 
proliferation, survival and ultimate fate determination of the CNCC play an 
important role in regulating craniofacial development. CNCC give rise to a 
variety of cell types during embryonic development. These cells eventually give 
rise to the hard tissues of the head such as bone, cartilage and teeth; optic 
elements such as the choroid, sclera, iris, and ciliary body, and sensory ganglia 
of the fifth, seventh, ninth and tenth cranial nerves (Noden, 1983; Couly et al., 
1993; Kontges and Lumsden, 1996) (Fig. 2). Genetic disorders, environmental 
insults, or a combination of both can alter the fate determination of CNCC 
leading to craniofacial malformations. 
CNCC arise uniformly at the dorso-lateral edge of the closing neural 
folds, along almost the entire length of the vertebrate embryo neural axis. This 
region corresponds to the interface between the non-neural ectoderm 
(presumptive epidermis or surface ectoderm) and the neural plate 
(neuroepithelium), a region that is commonly referred to as the neural plate 
border. CNCC induction requires contact mediated interactions between the 
surface ectoderm and neuroepithelium and each of these tissues contributes 
to the neural crest cell lineage (Selleck and Bronner-Fraser, 1995). In addition 
to their induction along the dorsolateral edge of the neural plate, neural crest 
cells undergo an epithelial to mesenchymal transformation whereby they 
delaminate from the neural tube and begin to migrate (Figs. 2, 3). These 
epithelial-mesenchymal transitions are marked by changes in cell adhesion and 
cytoarchitecture (Bronner-Fraser, 1993; LaBonne and Bronner-Fraser, 1999; Le 
Douarin et al., 2004). Following delamination from the neural tube, CNCC 
migrate along specific pathways to their final destinations (Fig. 4). In 
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vertebrates, the majority of CNCC are derived from the hindbrain, which 
migrate ventrolaterally from neural tube in three distinct sub-ectodermal 
streams adjacent to the even numbered rhombomeres (r2, r4, r6). The 
proliferative activity of the CNCC in the craniofacial region eventually leads to 
the formation of the frontonasal processes and discrete swellings that 
demarcate each branchial arch.  The three streams of CNCC populate the first, 
second and third branchial arches respectively in keeping with their 
craniocaudal axial origins (Lumsden et al., 1991) and give rise to a wide variety 
of cell lineages, which are distinct for each branchial arch (Noden, 1983; 
Kontges and Lumsden, 1996).  
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Figure 2: A schematic representation of early embryonic development. Panels 
A-D depict early development (at the third and fourth weeks of gestation) in 
which the neural plate (A), neural groove (B), and neural tube (C) are formed 
from the dorsal surface of the embryo. The left side of each panel depicts the 
developing embryo in a dorsal view, and the right side shows cross sections 
through the nervous system cut at the levels indicated by the arrows. Note 
also the cells formed from differentiated cells of the neural crest (D). 
 (Taken from http://what-when how.com/neuroscience/development-of-the-
nervous-system-gross-anatomy-of-the-brain-part-1/. Web. October 10th 2014).  
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Figure 3: Diagrammatic illustration of cranial neural crest cell formation and 
delamination.  
(REECE, JANE B.; URRY, LISA A.; CAIN, MICHAEL L.; WASSERMAN, STEVEN A.; 
MINORSKY, PETER V.; JACKSON, ROBERT B., CAMPBELL BIOLOGY, 9th Edition, 
© 2011. Reprinted and Electronically reproduced by permission of Pearson 
Education, Inc., Upper Saddle River, NJ). 
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Figure 4: A schematic demonstration of border induction and neurulation. 
The neural plate border (green) is induced by signalling between the 
neuroectoderm (purple) and the non-neural ectoderm (blue) and from the 
underlying paraxial mesoderm (yellow). During neurulation, the neural plate 
borders (neural folds) elevate, causing the neural plate to roll into a neural 
tube. Neural crest cells (green) delaminate from the neural folds or the dorsal 
neural tube (shown), depending on the species and axial level.  
(Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews 
Neuroscience., Neuro crest specification: migrating into genomics., copyright 
Oct 1, 2003.) 
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2.1.3 Formation of the face 
The face originates from five prominences that surround a central 
depression, the stomodeum, which constitutes the future mouth. These 
prominences include the single median frontonasal and the paired maxillary 
and mandibular prominences ; the latter two are derivatives of the first pair of 
six branchial arches. These prominences and arches arise in most part, from 
neural crest ectomesenchyme (neural crest cells) that migrates from the dorsal 
neural tube (point of fusion of the neural plate borders) into the facial and 
neck regions (Fig. 2).  
The frontonasal prominence surrounds the forebrain, which has lateral 
optic diverticula that form the eyes. The frontal portion of the prominence 
between the eyes forms the forehead; at the inferolateral corners, thickened 
ectodermal nasal (olfactory) placodes arise. These placodes become the 
olfactory epithelium and develop the underlying olfactory nerves.  Union of the 
facial prominences occurs by merging of the frontonasal, maxillary, and 
mandibular prominences. Merging of what are initially incompletely separated 
prominences occurs as the intervening grooves disappear as a result of 
migration into and proliferation of underlying mesenchyme in the groove. 
Fusion of the freely projecting medial nasal prominences with the maxillary 
and lateral nasal prominences on each side requires the disintegration of their 
contacting surface epithelia, allowing the underlying mesenchymal cells to 
intermingle. Failure of normal disintegration by cell death or mesenchymal 
transformation is a cause of cleft upper lip and primary palate, as such failure 
prevents the intermingling of maxillary and medial nasal mesenchyme. Fusion 
of the medial nasal and maxillary prominences provides for continuity of the 
upper jaw and lip and separation of the nasal pits from the stomodeum. The 
midline merging of the medial nasal prominences forms the median 
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tuberculum and philtrum of the upper lip, the tip of the nose, and the primary 
palate.  
The intermaxillary segment of the upper jaw (the premaxilla), in which 
the four upper incisor teeth will develop, arises from the median primary 
palate that is initially a widely separated pair of inwardly projecting swellings 
of the merged medial nasal prominences. Abnormal unilateral clefting resulting 
from failed fusion of medial nasal and maxillary prominences produces a 
deflection of the nose and upper lip.  
The lower jaw and lip are very simply formed by midline merging of the 
paired mandibular prominences and are the first parts of the face to become 
definitively established. The lateral merging of the maxillary and mandibular 
prominences creates the commissures (corners) of the mouth (Fig. 5) (Gilbert, 
2003; Lumsden and Keynes, 1989; Helms et al., 2005; Sperber and Sperber, 
2009; Hinrichsen, 1985).  
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Figure 5: A diagrammatic illustration of facial development Showing the 
prominences from which the structures of the face are formed.  The 
frontonasal or median nasal prominence (red) gives rise to the forehead (A), 
centre of the nose (B), philtrum of the upper lip (C) and the primary palate (D). 
The lateral nasal prominences (blue) form the sides of the nose (B,D). The 
maxillary and mandibular prominences (green) give rise to the sides of the 
middle and lower face, lateral borders of the lips, the secondary palate 
(specifically from maxillary prominences) and to the lower jaw (specifically 
from the mandibular prominences) (D). 
(REPRODUCED WITH PERMISSION FROM HELMS JA, CORDERO D, TAPADIA MD. 
(2005). NEW INSIGHTS INTO CRANIOFACIAL MORPHOGENESIS. DEVELOPMENT 
132:851–861). 
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2.2 Secondary palate development 
The primary and secondary palates form the main barrier between 
mammalian nasal and oral cavities. This was an evolutionary advancement 
from the single common chamber seen in birds and reptiles (Chong et al., 2002 
and Sperber et al., 2002). The secondary palate (SP) is the primordium of both 
the hard and soft palates of the palate. SP development is a multi-step process 
involving palatal shelf growth, elevation, midline fusion of the two palatal 
shelves and the disappearance of the midline epithelial seam (MES). The 
palatal structures are composed of the cranial neural crest (CNC-derived 
ectomesenchyme and pharyngeal ectoderm) (Ferguson, 1988; Shuler, 1995).  
Palatal shelves are covered by epithelia that can be divided into the 
nasal, oral and medial edge epithelium (MEE). The nasal and oral epithelia 
differentiate into pseudostratified columnar and stratified squamous epithelia 
respectively, whereas the medial edge epithelium gets removed by means of 
programmed cell death (apoptosis) and cell migration (Martinez-Alvarez et al., 
2000; Vaziri Sani et al., 2005).  
Secondary palate development begins at E11.5 in mice and around the 
sixth week of gestation in humans. Initially, the palatal shelves exist as 
projections in the internal aspects of the maxillae, on either side of the tongue. 
These two shelves then grow vertically downwards on either sides of the 
tongue between the stages E12.0 and E13.5 (Ferguson, 1988; Berkovitz,et al., 
2002). As the jaws develop, the tongue depresses causing the palatal shelves 
to re-orient themselves above the tongue at E14.0. The shelves then start 
growing horizontally towards each other where they ultimately touch at E14.5 
to form the midline epithelial seam (MES). The MES degrades by E15.5 leaving 
behind a confluent SP (Fig. 6). 
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Figure 6: A schematic illustration of secondary palate development showing 
the palatal shelves emerging from the maxillary prominences at E11.5, growing 
vertically downwards on either side of the tongue (E12.5), re-orienting above 
the tongue (E13.5-E14.0), growing horizontally and touching to form the 
midline epithelial seam (E14.5) and eventually fusing to form a solid, confluent 
secondary palate (E15.5). ps- Palatal shelf, T-tongue. 
(REPRODUCED WITH PERMISSION OF THE AMERICAN SOCIETY OF CLINICAL 
INVESTIGATION IN THE FORMAT REPUBLISH IN A THESIS/DISSERTATION VIA 
COPYRIGHT CLEARANCE CENTRE). 
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2.3 Molecular signalling in the developing palate 
Mammalian SP development is an intricate process involving the 
participation of several transcription factors and growth factors that interact 
with their receptors as well as with each other. These networks work together 
to regulate critical cellular processes including cell proliferation, migration and 
epithelial-mesenchymal transdifferentiation and apoptosis. Similar to the 
development of other organs in the embryo, SP palate development relies on 
the sequential and reciprocal epithelial-mesenchymal interactions. Some of 
the transcription factors and growth factors involved in SP development 
include; Shh, Msx1, Bmp4, Barx1, Fgf10, Fgf receptors, Pax9, Osr2 and Tgfβ. 
 Shh is a member of the hedgehog family of secreted proteins which 
plays crucial roles in diverse developmental processes including left-right axis 
establishment, dorso-ventral patterning of the neural tube, endoderm 
development, A-P patterning of the developing limb, brain development and 
patterning (McMahon et al., 2003; Roessler and Muenke, 2003). Shh is 
expressed at all stages of SP development and follows a striped pattern of 
expression corresponding to areas of thickened epithelium that later form the 
palatal rugae. The A-P outgrowth of palatal shelves has been associated with 
periodic formation of palatal rugae and is controlled by reciprocal epithelial-
mesenchymal crosstalk along the A-P axis (Lan and Jiang, 2009; Pantalacci et 
al., 2008; Welsh and O’Brien, 2009). Palatal rugae have been reported to 
express high levels of Shh in addition to acting as signalling centers involved in 
epithelial-mesenchymal interactions required to coordinate palate outgrowth 
and patterning (Lan and Jiang, 2009; Rice et al., 2006; Welsh and O’Brien, 
2009). A study by Han et al., 2009 reported that the epithelial cells expressing 
Shh are not actively proliferating, but the mesenchymal cells underlying these 
regions are more highly proliferative than mesenchymal cells in other areas of 
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the palate. Shh is a downstream target of the Msx1 network that regulates cell 
proliferation in the anterior palate (Zhang et al., 2002).  
 Loss of the Spry2 gene has been associated with the disorganization in 
the expression pattern of Shh, which ultimately leads to deformities in the 
rugae in the palate of these knockout animals (Welsh et al., 2007). Studies of 
mice involving epithelium-specific inactivation of Shh or mesenchyme-specific 
inactivation of smoothened (Smo), which encodes a transmembrane protein 
required for transducing Shh signalling, have demonstrated that Shh signals 
from the epithelium to the underlying mesenchyme to promote palatal cell 
proliferation and outgrowth (Rice et al., 2004; Lan and Jiang, 2009). In addition, 
the exogenous application of Shh has been shown to induce a mitogenic 
response in palatal explant cultures (Zhang et al., 2002; Rice et al., 2004). This 
mitogenic effect is mediated, in part, by the cell cycle regulators Cyclin D1 and 
Cyclin D2, the expression of which was reduced in the palatal mesenchyme of 
embryos with mesenchyme-specific inactivation of Smo.   
 Lan and Jiang, (2009) reported that Shh from palatal epithelial cells 
stimulates cell proliferation and the expression of Fgf10 in the developing 
palatal mesenchyme. Shh and Fgf10 have also been reported to function in a 
positive-feedback loop to drive the outgrowth of the palatal shelves (Bush and 
Jiang., 2012; Lan and Jiang., 2009; Rice et al., 2004). The expression of Foxf1a 
and Foxf2 and Osr2 genes was also reduced in the palatal mesenchyme, 
indicating that these transcription factors might be downstream effectors of 
Shh signalling (Lan and Jiang, 2009). Fgf10 is a crucial mesenchymal signal that 
is required for palatal outgrowth. Mice homozygous for a null mutation in 
either Fgf10 or the gene encoding its receptor, Fgfr2b, exhibited cleft palate 
with impaired palatal shelf outgrowth (Rice et al., 2004). Whereas Fgf10 mRNA 
expression was restricted to the mesenchyme, Fgfr2b mRNA was most 
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abundantly detected in the overlying epithelium. Fgfr2 function is required 
within the epithelium, as mice harbouring an epithelial-specific deletion of 
Fgfr2 also exhibited cleft palate (Hosokawa et al., 2009). Both epithelial and 
mesenchymal cell proliferation were reduced in the absence of either Fgf10 or 
Fgfr2b, however, suggesting the presence of a factor that signals from the 
epithelium back to the underlying mesenchyme and that is dependent on 
Fgf10/Fgfr2b signalling. Indeed, Shh expression was dramatically reduced in 
the epithelium of Fgf10 null and Fgfr2b null embryos, implying that the 
decreased palatal mesenchymal cell proliferation observed in these mutants 
might be a consequence of reduced Shh expression in the epithelium (Rice et 
al., 2004). The expression of Fgf10 was also reduced in the palatal 
mesenchyme of embryos lacking mesenchymal Smo, indicating that Shh and 
Fgf10 function in a positive-feedback loop that drives the outgrowth of the 
palatal shelves (Lan and Jiang, 2009). 
 In addition, cross-regulation of the Shh and Bmp signalling pathways has 
also been detected in the developing palate (Baek et al., 2011; Lan and Jiang, 
2009; Zhang et al., 2002). The loss of Smo within the palatal mesenchyme led 
to up regulation of Bmp4 and down regulation of Bmp2 (Lan and Jiang, 2009). 
The positive regulation of Bmp2 by Shh signalling is consistent with the finding 
that exogenous Shh-containing beads induce Bmp2 expression in palatal 
explant culture (Zhang et al., 2002). Whereas complete inactivation of Bmp4 
resulted in early embryonic lethality, ablation of Bmp4 function in the maxillary 
mesenchyme and throughout the oral epithelium caused a cleft lip phenotype, 
but no secondary palate defect was reported (Liu et al., 2005). Overexpression 
of the Bmp antagonist noggin specifically in the palatal mesenchyme led to 
retarded palatal growth and cleft palate in mice (Xiong et al., 2009), further 
supporting the involvement of Bmp signalling during palatal growth. Studies 
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have also shown that Bmp signalling during palatogenesis occurs via the type I 
Bmp receptor Bmpr1a. Disruption of Bmpr1a in the maxillary mesenchyme and 
throughout the oral epithelium resulted in cleft lip and palate (Liuet al., 2005).  
 Pax9 is a member of the transcription factor family characterized by the 
paired-class DNA binding domain (Stapleton et al., 1993). Pax9-deficient mice 
have been reported to die shortly after birth, exhibiting complete cleft palate 
(Peters et al., 1998). Yu et al., 2013 reported that Pax9 regulates epithelial-
mesenchymal signalling and A-P patterning during palate outgrowth and that 
Pax9 acts upstream of Osr2 to regulate palatal shelf growth and elevation. In 
addition, this study also reported that Pax9 acts upstream of Bmp4, Fgf10, 
Msx1 and Osr2 in the palatal mesenchyme.  
 
2.4 Molecular signalling along the A-P axis of the developing SP 
Although the palatal shelves appear as continuous outgrowths that 
project from the maxillary processes into the oral cavity, studies have revealed 
differential gene expression along the A-P axis, and that this heterogeneity is 
evident from the early stages of palatal outgrowth (Hilliard et al., 2005; Li and 
Ding, 2007; Welsh and O’Brien, 2009; reviewed in Smith et al., 2013). The SP 
may be divided into three regions along the A-P axis, namely the anterior 
palate, medial palate and posterior palate. A number of different systems of 
nomenclature have been used to demarcate the boundaries of the anterior, 
medial and posterior regions of the SP.  In this thesis, I will follow the 
nomenclature proposed by Smith et al., (2013) which defines the anterior and 
posterior palate as tissue lying anterior or posterior to the first molar tooth 
bud, respectively. The medial palate is defined as palate tissue in the plane of 
the molar tooth bud.  
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Several transcription factor genes are differentially expressed along the 
A-P axis of the developing palatal shelves. The development and maintenance 
of the expression of these genes in a region specific manner is critical for 
normal SP development. Msx1, Bmp4, Bmp2, Shh, Spry2, Fgf10, Fgf7, Shox2 
genes are preferentially expressed in the anterior palatal mesenchyme 
(Alappat et al., 2005; Rice et al., 2004; Yu et al., 2005; Zhang et al., 2002), 
whereas Barx1, Mn1, Meox2, Tbx22 genes are preferentially expressed in the 
posterior palatal mesenchyme (Barlow et al., 1999; Li and Ding, 2007; Liu et al., 
2008).  Although mice lacking either Msx1 or Mn1 exhibited complete cleft 
palate, Msx1 null mice exhibited specific cell proliferation defects in the 
anterior region, whereas Mn1 null mice showed growth deficits in only the 
middle and posterior regions of the palatal shelves (Zhang et al., 2002; Liu et 
al., 2008). Mice lacking Shox2 exhibited a cleft within the anterior palate, 
whereas the posterior palate fused normally, demonstrating a specific 
requirement for Shox2 in anterior palatal outgrowth (Yu et al., 2005). Tbx22 
null mice displayed cleft palate, with the severity varying from a complete cleft 
palate phenotype due to decreased palatal shelf extension to submucous cleft 
palate (abnormal muscle orientation in the soft palate during midline fusion) in 
which palatal shelf elevation and fusion occurred normally (Pauws et al., 2009). 
The expression of Msx1 and Shox2 in the anterior palatal mesenchyme 
depends on Bmp signalling, as expression of both these genes was significantly 
reduced in the anterior palate of Wnt1-Cre; Bmpr1af/– mice (Li et al., 2011).   
 
Most studies on palatal outgrowth have focused on the downward 
growth of the palatal shelves; however, the maxillary processes also undergo 
significant rostrocaudal expansion from E12.5 to E14.5, and the palatal shelves 
correspondingly elongate along their A-P axis. As the palatal shelves elongate, 
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the domain of Shox2 mRNA expression expands much more dramatically than 
that of Meox2 (Li and Ding, 2007). It has been demonstrated that the A-P 
boundary of Shox2 and Meox2 expression coincides with the first formed 
palatal rugae (Pantalacci et al., 2008; Welsh and O’Brien, 2009). The rugae are 
metameric epithelial thickenings on the oral surface of the palate that are first 
apparent at E12.0 and develop by periodic interposition as the palatal shelves 
elongate along the A-P axis (Pantalacci et al., 2008). Whereas the second and 
third rugae form sequentially and anteriorly to the first ruga, the fourth ruga 
forms between rugae 1 and 2, and, as the palatal shelves continue to elongate 
along the A-P axis, subsequent rugae formation only occurs between the newly 
formed ruga and ruga 1 (Pantalacci et al., 2008; Welsh and O’Brien, 2009). 
Depending on the strain background, mice develop a total of nine or ten rugae, 
which are maintained after birth.  
 
2.5 Molecular signalling along the O-N axis of the developing SP 
The developing palatal shelves also exhibit molecular heterogeneity 
along the O-N axis during vertical outgrowth with the lateral side forming the 
oral palatal mesenchyme and the medial side forming the nasal palatal 
mesenchyme following palatal shelf elevation. Palatal rugae begin to form on 
the oral side of the developing palatal shelves at E12.0, and the expression of 
Shh becomes restricted to the oral palatal epithelium. Osr1 and Osr2 exhibit 
graded expression in the developing palatal mesenchyme along the oral-nasal 
axis (Lan et al., 2004). At E13.5, Osr1 mRNA expression is restricted to the oral 
side, whereas Osr2 exhibits graded expression that is strongest in the oral 
mesenchyme and weaker in the nasal mesenchyme (Yu et al., 2013). Whereas 
Pax9 is expressed throughout the O-N axis of the palatal mesenchyme in the 
posterior region, its expression has been reported to be lower in the oral half 
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than in the nasal half of the palatal mesenchyme in the anterior region (Yu et 
al., 2013). Dlx5 has also been implicated in O-N patterning and palatal 
expansion. Dlx5 is co-expressed with Fgf7 in the oral half of the palatal 
mesenchyme, and Fgf7 expression was found to be dramatically reduced in 
this domain in Dlx5 null palatal shelves (Han et al., 2009). Although Dlx5 null 
palatal shelves elevated and fused, the oral aspect of the palate was 
dramatically expanded and a malformed soft palate was observed (Han et al., 
2009).  
 
2.6 The Six family of genes 
The Six gene family consists of vertebrate genes that have sequence 
similarities to the Drosophila homeobox gene, Sine oculis (So). These genes are 
characterized by the presence of a divergent DNA-binding homeodomain (HD, 
60 amino acids) and an upstream region, the Six domain (SD, 110-115 amino 
acids), that could be involved in both determining DNA binding specificity and 
in mediating protein-protein interactions (Fig. 7). In mammals, several 
members of the family have been cloned and designated Six1 to Six6 (Boucher 
et al., 1995,1996; Oliver et al., 1995; Gallardo et al., 1999; Granadino et al., 
1999; Kawakami et al., 1996). The Six and homeodomain regions are highly 
conserved across the Six family, while other regions of these proteins are often 
conserved across vertebrate species, but not between family members. Mouse 
Six1 and Six2 exhibit a high degree of sequence similarity to each other (95% 
amino acid sequence identity over a region spanning the Six domain and 
homeodomains) and they also show a higher degree of sequence similarity to 
Drosophila Sine oculis (So) (87 and 95%, respectively, over the same region) 
than do other family members. Six1 and Six2 thus represent orthologues of 
Sine oculis (Oliver et al., 1995). Their expression patterns, however, differ from 
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that of So, which is primarily expressed in the developing visual system of the 
fly. In mice, fetal expression studies have demonstrated that neither Six1 nor 
Six2 is expressed in the developing eye, rather, there is notable expression in 
anterior neural structures, neural crest derived tissues, and head, trunk and 
limb mesenchyme, with Six1 and Six2 transcripts appearing to occupy 
complementary axial domains in the phalanges (Oliver et al., 1995; Ohto et al., 
1998).  
 
2.7 Expression patterns of Six genes 
Six genes are diversely expressed during vertebrate embryogenesis and 
control the formation of various organs. In most cases, they positively regulate 
cell numbers within the developing embryo by promoting cell proliferation and 
survival and mainly act as transcription factors (Christensen et al., 2008; 
Kawakami et al., 2000).  
In the mouse embryo, Six3 and Six6 are expressed in restricted areas: 
developing eye, brain and a few related sites. The expression patterns of these 
two mouse Six genes appear to share similar characteristics with Drosophila 
Optix, whose expression is detected only in the cephalic region of the embryo. 
In contrast, Six1, Six2 and Six4 show much broader expression. Six1 and Six4 
show remarkably similar patterns of expression. They are expressed in two of 
the sensory organs in the head region (otic vesicles and nasal pits) and in the 
branchial arches. In addition, the expression of Six1 and Six4 extends 
posteriorly in dorsal root ganglia and somites which give rise to the skeletal 
muscle of the trunk and limbs. The expression in somites is similar to 
mesodermal expression of So and D-Six4 in Drosophila. Six2 is also expressed 
caudally in certain tissues, in addition to the rostral and cervical regions. For 
Six5, the expression pattern was studied by using transgenic mice carrying a 
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transgene containing its 4.3 kb promoter fragment fused to the lacZ reporter 
gene (Fig. 8). The mice showed expression of the reporter lacZ in neural, 
sensory, muscle, cartilage and other tissues (Heath et al., 1997). 
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Figure 7: A schematic illustration of the human SIX2 gene structure showing 
transcribed exonic sequences present in cloned cDNA (boxes) and the relative 
locations of the sequences encoding the SIX-(SIX) and homeodomains (HD). 
(Reproduced with permission from Boucher, C., Carey, N., Edwards, Y., 
Siciliano, M. and Johnson, K. (1996). Cloning of the human SIX1 gene and its 
assignment to chromosome 14. Genomics 33: 140-142., via Elsevier and 
copyright clearance centre). 
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Figure 8: A schematic drawing of embryonic Expression patterns and 
chromosomal locations of mouse Six family genes. Similarity in the colour of 
shadings reflects similarity in the expression patterns. DRG, dorsal root 
ganglion; FB, forebrain; FL, forelimb; GE, genital eminence; HL, hindlimb; NC, 
nephrogenic cord; NP, nasal placode; OC, optic chiasm; OP, optic vesicle; OV, 
otic vesicle; RP, Rathke's pouch; SO, somites. B: Expression of Six3 and Six6 in a 
developing eye (E13.5). LE, lens; NR, neural retina; RPE, retinal pigmented 
epithelium. C: Chromosomal localization of mouse Six family genes.  
Reproduced with permission from Kawakami, K., Sato, S., Ozaki, H. and Ikeda, 
K. (2000). Six family genes–structure and function as transcription factors and 
their roles in development. BioEssays 22:  616-626., via John Wiley and Sons 
and Copyright clearance centre. 
  
 
 
 
 
 
 
 
28 
 
2.8 SIX genes and genetic diseases 
Holoprosencephaly (HPE) is a common malformation found in 
spontaneously aborted fetuses (1/250) and more rarely in live births 
(1/16,000). It is characterized by signs of abnormal development such as 
malformation of the brain, a single central incisor, hypotelorism, microcephaly 
and other craniofacial abnormalities (Roessler et al., 1998).  
When the mouse Six3 gene was mapped to the distal region of 
chromosome 17, (Oliver et al., 1995) which is orthologous to human 2p21 
where the HPE2 locus resides, the possibility that the SIX3 gene is involved in 
HPE was suggested. This idea was confirmed by the isolation of the SIX3 gene 
from the HPE2 minimal critical region and the identification of four point 
mutations associated with HPE2 in the coding region of SIX3. All of those 
mutations were identified in the HD of SIX3; L226V and del(N232-S234) change 
amino acid residues unique to the SIX3/6 subfamily while V250A and R257P 
change residues common to all Six proteins (Wallis et al., 1999). This strongly 
suggested that SIX3 is the HPE2 gene essential for the development of the 
anterior neural plate and eye in humans.  
Human SIX6 haploinsufficiency was found to be responsible for bilateral 
anophthalmia, the absence of the optic nerve and chiasma, and for pituitary 
abnormalities (Gallardo et al., 1999). One such patient was found to have 
interstitial deletions of the 14q22.3-q23 chromosomal region. The regulatory 
region and the coding region of SIX6 were both deleted in one chromosome 14 
of that patient. The relationships between SIX3/6 subfamily genes and several 
other genes implicated in HPE, such as SHH, (Belloni et al., 1996) Zic2,(Brown 
et al., 1998) and TG-interacting factor (TGIF) (Walsh et al., 1999) have not yet 
been clarified.  
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Myotonic dystrophy (DM) is characterized by muscle weakness, wasting 
and disturbances in the nervous system (Harris et al., 1996). In addition, DM is 
associated with ophthalmic features such as cataract, as well as cardiac 
conduction defects, mental impairment, premature balding and reduced 
fertility. SIX5 was originally identified as DMAHP (DM associated 
homeodomain protein gene), which resides downstream of the causative CTG 
repeat located on 19q13.3 (DM1) (Boucher et al., 1995). Expansion of the CTG 
repeat results in increased severity of symptoms and an earlier age of onset. 
The CTG expansion at this locus has been proposed to alter the local chromatin 
structure and to repress the transcription of surrounding genes (Otten et al., 
1995).  
The expression of SIX5 was reduced 2- to 4-fold in cells derived from 
DM1 patients relative to wild-type controls (Klesert et al., 1997; Thornton et 
al., 1997). At least some symptoms were believed to be caused by down-
regulation of SIX5, which in turn leads to aberrant regulation of the SIX5 target 
genes. For example, the observation that myogenin expression is up-regulated 
most efficiently by Six5 and Eya3 (one of the Eya family proteins in mouse) 
through the MEF3 site in the proximal promoter suggests the involvement of 
SIX5 in muscle phenotype. The expression of SIX5 but not DMPK in human lens 
also suggests the involvement of SIX5 in the formation of cataracts 
(Winchester et al., 1999). The involvement of DMPK (DM protein kinase) and 
DMWD (DM protein with WD repeat), genes located 50 bp downstream to the 
CTG repeat, has also been suggested which would indicate that DM1 is a multi-
gene disorder (Winchester et al., 1999; Alwazzan et al., 1999). 
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2.9 The Six2 gene 
Six2 is a homeobox transcription factor that is expressed in multiple 
organ systems of the developing embryo. This gene has been shown to be 
involved in regulating craniofacial and kidney development (Fogelgren et al., 
2008; Fogelgren et al., 2009; Lozanoff, 1993; Lozanoff et al., 2001; Ma and 
Lozanoff, 1996; Ma and Lozanoff, 1999; McBratney et al., 2003; Singh et al., 
1998).  In addition, Six2 has been reported to be expressed in the nasal 
prominences of E11.5 mice (Brodbeck et al., 2004; Fogelgren et al., 2008; Ohto 
et al., 1998; Oliver et al., 1995). Six2 has been shown to be a downstream 
target of the Hox11 proteins in metanephric kidney development. In the early 
metanephric mesenchyme, Hox11 proteins interact with Pax2 and Eya1 to 
promote activation of Six2 (Gong et al., 2007; Wellik et al., 2002).  It has also 
been reported that Six2 null mice die at birth and exhibit a shorter cranial base. 
In addition, these mice were also found to have defects in third and fourth 
branchial arch derived cartilages (Guiyuan et al., 2010). Six2 has been reported 
to positively regulate cell numbers within the developing embryo by promoting 
cell proliferation and survival (Christensen et al., 2008; Kawakami et al., 2000). 
Six2 has been implicated in kidney development where it maintains the renal 
progenitor cell population in an undifferentiated state (Self et al., 2006).  
 The epigenetic  regulation of Six2 by micro RNAs has also been 
reported. Lyu et al., (2013) reported that miR-181b directly targets the 3’UTR 
of Six2 to downregulate its expression at both the mRNA and protein level in 
the kidney mesenchyme. In addition,  Xiaoyan et al., (2014) have also reported 
that a single micro RNA (miRNA), miR181c was able to down regulate the 
expression of Six2 in the kidney mesenchyme and thus restraining cell 
proliferation and promoting apoptosis. Furthermore, Six2 has been reported to 
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promote breast cancer metastasis through the transcriptional and epigenetic 
control of E-cadherin expression (Wang et al., 2014).  
Six2 is a direct downstream target of Hoxa2, a gene that plays a direct 
role in murine secondary palate development (Smith et al., 2009). Expression 
of Six2 in wild type embryos is restricted to the first branchial arch 
mesenchyme. Loss of function of Hoxa2 results in an expansion of Six2 
expression in the branchial arches and periodic mesenchyme and leads to 
malformations of the middle and external ear (Kujetova et al., 2005; Rijli et al., 
1993). This implies that Hoxa2 expression is sufficient to repress the expression 
of Six2 (Santagati et al., 2005). Interestingly, when Six2 is overexpressed in the 
areas of the embryo controlled by Hoxa2, the result is a phenotype similar to 
the Hoxa2 mutant phenotype. Analysis of the promoter region of Six2 in 
combination with ChIP experiments suggests that Hoxa2 directly represses the 
expression of Six2 (Kutejova et al., 2005; Kutejova et al., 2008).  
The studies above show the extent to which the Six2 gene has been 
studied in mammalian development. Most of these studies have focussed on 
kidney development and craniofacial development in general.  However, no 
detailed expression analysis of Six2 has been performed in the developing 
secondary palate. In addition, its precise role in the craniofacial region and 
especially in the developing mammalian secondary palate is still unknown. My 
thesis therefore seeks to address these gaps in knowledge regarding the 
transcription factor Six2 during murine palatogenesis. 
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3. HYPOTHESES 
1. Development of the secondary palate is accompanied by changes in the 
temporal and spatial expression patterns of Six2 gene transcripts and 
protein.  
2. The Six2 gene and protein are up-regulated in the absence of the Hoxa2 
gene in the secondary palate.  
3. The Six2 gene regulates cell proliferation during secondary palate 
development.  
 
 
4. OBJECTIVES 
1. To study the temporal and spatial expression pattern of the Six2 gene 
and protein in the developing secondary palate.  
2. To investigate whether Six2 mRNA and protein are altered in the 
absence of the Hoxa2 gene in the secondary palate  
3. To determine if the Six2 gene regulates cell proliferation during 
secondary palate development.  
 
 
 
 
 
 
 
 
 
33 
 
5. MATERIALS AND METHODS 
5.1 Hoxa2 transgenic mice 
Hoxa2 +/+, Hoxa2+/- and Hoxa2 -/- C57 black mice (Gendron-Maguire et al., 
1993) were obtained by timed heterozygous matings. Heterozygous animals 
were obtained by backcrossing heterozygous males with wild-type females. 
After pups were weaned, animals were anaesthesized using isoflurane 3% in 
oxygen and approximately 0.2 cm piece of the tail was docked. Genotypes 
were confirmed by polymerase chain reaction (PCR) analyses (Appendix Fig. 2). 
Timed heterozygous matings were then performed, and were staged according 
to Kaufman with mice being considered E0 days pregnant on the day the 
vaginal plug was found (Kaufman, 1992).  
 
5.2 PCR analysis of genotype 
Tissue sample (tail or embryonic tissue) was digested overnight at 55°C 
in a solution containing 0.5M EDTA, Nuclei lysis solution (Promega) and 20 
mg/ml proteinase K enzyme. Following the digestion, samples were allowed to 
cool to RTM after which protein precipitation solution (Promega) was added 
and the solution vortexed vigorously at high speed for 20 sec. Solution was 
then chilled on ice for 5 min followed by centrifugation for 4 min at 14,000 x g. 
The precipitated protein formed a tight white pellet. The supernatant 
containing the DNA was then carefully removed (leaving the protein pellet 
behind) and transferred into a clean 1.5ml microcentrifuge tube containing an 
equal volume of isopropanol at RTM. The solutions were then mixed gently by 
inversion until the white thread-like strands of DNA formed a visible mass. The 
solutions were centrifuged for 1 min at 14,000 x g at RTM. The supernatant 
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was carefully decanted and the DNA was visible as a small white pellet. Ethanol 
(70% ) at RTM was then added and the tubes gently inverted several times to 
wash the DNA. The solutions were centrifuged again for 1 min at 14,000 x g at 
RTM. Ethanol was then carefully aspirated using a Pasteur pipette and the 
pellet air dried for 10-15 min. The DNA was then rehydrated by adding DNA 
rehydration solution (Promega) and incubating at 65°C for 1 h. DNA was then 
analyzed by PCR to determine the genotype of the animal. Each sample was 
amplified in two different PCR reactions, one to determine the presence of the 
wild-type Hoxa2 allele (5´-GTTGGAACTGACCTCCTCTTG-3´ and 5´-
GGGTCCGAGCAGGGTTATTCC-3´) and the other to detect the presence of the 
neomycin cassette that replaces part of exon 1, all of intron 1 and part of exon 
2 in the knockout animals (5´-TCGCCTTCTATCGCCTTCTTG-3´ and 5´-
GTTGGTGTACGCGGTTCTCAG-3´). PCR reactions (50 μl) containing 10X 
amplification buffer (Invitrogen), 2 mM dNTP mix (Sigma), 1μM of each primer 
(Invitrogen) and 2.5 U of Taq polymerase enzyme (VWR) and 1 μg of DNA were 
prepared. Reactions were run on the BioRad MyCyclerTM using the 
temperature cycling conditions 95°C for 4 min followed by 35 cycles of 95°C for 
30 s, 65°C for 3 min and 72°C for 7 min (Gendron-Maguire et al., 1993). PCR 
samples were then separated on a 1% agarose gel containing RedsafeTM 
(Frogga Bio) and visualized using UV light.  
 
5.3 Immunohistochemistry (IHC) 
Embryos were harvested from timed-pregnant mice, and heads were 
fixed in 4% paraformaldehyde in phosphate buffered saline (PBS, pH7.4) for 24 
h. Embryo heads were then placed in 30% sucrose in PBS for at least 24 h (or 
after sinking to bottom of well) before being embedded in optimal cutting 
temperature (OCT) compound (Tissue-Tek) and serially sectioned (in a coronal 
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plane) on to 0.5% gelatin coated glass slides. Determination of anterior, medial 
and posterior was performed by matching to sections from each region (Rice et 
al., 2004; Smith et al., 2013). Sections were then allowed to dry at RTM for at 
least 2 h. The 8 μm thick sections were then rehydrated for 45 min in 1xPBS 
and blocked in 4% skim milk powder and 0.1% Triton X-100 in PBS for 30 min at 
RTM. Sections were then exposed to the primary antibody diluted in PBS 
overnight at 4°C using the following antibodies; Six2 rabbit polyclonal antibody 
(ProteintechTM; 1:500), E-cadherin rat monoclonal antibody (SigmaTM ; 1:200) 
and Ki-67 rat monoclonal antibody (Affymetrix eBioscience; 1:200). Excess 
unbound primary antibody was rinsed off by two 5 min washes in PBS before 
being exposed to a labelled secondary antibody for 1.5 h at RTM (IgG Alexa 
fluor 488 antibody,1:200 or IgG Alexa fluor 594, 1:400; InvitrogenTM). Finally, 
sections were rinsed two more times in PBS, mounted in ProLong® Gold 
antifade reagent with DAPI (Molecular Probes) and viewed by fluorescence 
microscopy. To ensure that the signal observed was not the result of non-
specific signal from the secondary antibody, negative controls were performed. 
These included staining in the absence of the primary antibody, and another 
set where the secondary antibody was omitted.  
 
5.4 RNA Isolation and Reverse Transcription  
Total RNA was isolated from excised wild-type and Hoxa2 null embryo 
palate shelves using the RNeasy® Protect Mini Kit (Qiagen) as per the 
manufacturer’s protocol. RNA concentration was determined by optical 
density (Nanovue, General Electric). First strand DNA synthesis was performed 
using the SuperScript® first-strand synthesis system for RT-PCR (Invitrogen), 
using random decamer primers, as per the manufacturer’s protocol. Final 
concentration of RNA for all RT reactions was 20 ng/μl. 
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5.5 Quantitative Real Time RT-PCR  
Gene expression analysis was performed as previously described by 
Smith et al., 2009. Briefly, Taqman® primers  and labelled probe systems 
(Applied Biosystems) and a real time PCR machine (ABI 7300) from Applied 
Biosystems were used for real time PCR analysis of Six2, Msx1, Bmp4, Barx1 
and Ptx1. Palatal shelves were aseptically dissected from both wild-type and 
Hoxa2 null mice at stages E12.5, E13.5, E14.5 and E15.5. All reactions were 
performed using the Taqman Universal Master Mix (2X), FAM-labelled Taqman 
Gene Expression assays for Six2, Msx1, Bmp4, Barx1 and Ptx1, VIC-labelled 
Taqman Endogenous Control β-Actin, and 10ng of cDNA. All reactions were run 
in replicates of 5 (5 samples, each from a different embryo). Thermocycling 
parameters  were as follows: 2 min at 50oC, 10 min at 95 oC, 40 cycles of 15s at 
95 oC followed at end with one cycle  at 60 oC for 70s. Taqman gene expression 
assays have all been tested to have efficiencies not significantly different from 
1 (Applied Biosystems, 2004). However, in order to ensure that all primer sets 
were working properly and that multiplexing the gene specific and β-Actin 
primers did not result in altered amplification efficiencies all primer sets were 
examined individually and in complex with β-Actin.  
 
5.6 Droplet digital PCR (ddPCR) 
The procedure for PCR analysis using droplet digital PCR was performed 
as described by Hindson et al., 2013. Briefly, each 20 μl PCR reaction was 
loaded into an 8-channel, single-use consumable droplet generation cartridge. 
Oil (60 μl) containing emulsion-stabilizing, biocompatible surfactant was 
loaded into adjacent oil wells and the microfluidic chip was loaded into a beta-
series prototype droplet generator (DG). The DG applies a vacuum to the 
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outlet well creating a pressure difference across the cartridge that 
simultaneously partitions the sample present in each of the 8 wells into 
approximately 20,000 monodisperse droplets of accurately known volume. 
This process occurs at a rate of approximately 1,000 droplets/s per well. The 
resulting water-in-oil emulsions were pipette-transferred from the outlet well 
to a 96-well polypropylene plate (Eppendorf), sealed with foil and then 
amplified to endpoint using a Tetrad2 Peltier Thermal Cycler (Bio-Rad) and the 
cycling protocol: 95 °C for 10 min then 40 cycles of 95 °C for 15 s and 60 °C for 
1 min (2.5 °C/s ramp rate) with a final 10 min hold at 98 °C. Plates containing 
amplified droplets were loaded into a QX 100 droplet reader (Bio-Rad), which 
aspirates droplets  from the 96-well plate, one well at a time, and streams 
them single file (about 1,500 droplets/s) past a two-color detector of FAM and 
VIC fluorescent dyes (Life Technologies) sampling at 100 kHz. Discrimination 
between droplets that did not contain target (negatives) and those that did 
(positives) was achieved by applying a global fluorescence amplitude 
threshold. Concentration estimates were based on the fraction of droplets 
where amplification has occurred modelled as a Poisson distribution. 
 
5.7 Western blot analysis                                                                                        
  Palatal shelves were aseptically dissected from both wild-type and 
Hoxa2 null mice before being pooled together prior to lysis in radio-immuno 
precipitation assay [RIPA] buffer containing protease inhibitor (150 mM NaCl, 
10 mM Tris, 0.1%-SDS, 1% Triton X-100, 1% Deoxycholate, 5 mM EDTA). 
Protein was quantified using the Bradford assay to ensure that equal loading 
was achieved. Samples were then boiled for 15 min with loading buffer and 
loaded on a 10% polyacrylamide-SDS gel. After gel separation, the proteins 
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were transferred to a PolyScreen PVDF membrane, which was subsequently 
blocked by overnight incubation in 5% skim milk in PBS (SM-PBS) at 4°C. 
The membrane was then exposed to a Six2 primary antibody (Six2 rabbit 
polyclonal, Protein tech, 1:2000 in 5% skim milk in PBS) and incubated for 1 h 
at RTM. This was followed by 4 consecutive washes of 15 min each in PBS with 
0.08% Tween-20. After the washes were complete, the membrane was 
incubated with a secondary antibody specific to the species of the primary 
antibody that is used (anti-rabbit IgG horseradish peroxidase conjugate (Bio-
Rad) 1:3000) in SM-PBS for 1 h at RTM. After 4 washes of 15 min each in PBS-
Tween-20, membrane was exposed with a chemiluminescence reagent (ECL 
substrate, BIORAD) and the signal was detected using the SYNGENE imager. 
The membrane was then washed overnight at 4°C in PBS before being 
incubated with the anti-β-tubulin (Development Studies Hybridoma Bank, U. 
Iowa) at a dilution of 1:2000, and incubated for 1 h at RTM, followed by 4 
washes of 15 min each in PBS with 0.08% Tween-20. After the washes, the 
membrane was exposed to the anti-mouse IgM horseradish peroxidase 
conjugate (Bio-Rad) in SM-PBS at a dilution of 1:1500, and then treated as 
indicated above.  
After imaging, semi-quantitative densitometry was performed using the 
AlphaImager densiometric software to determine an integrated density value 
 (IDV) for each band. Four separate western blot assays, each having wild-type 
and Hoxa2 null samples of E12.5, E13.5, E14.5, E15.5 were performed. The 
software allowed for the selection of a representative background area and 
then to define an area around the bands of interest. Equal size boxes were 
used in all comparisons. To compare expression, relative IDV values for each 
blot were calculated by normalizing to β-tubulin levels from the same sample. 
The resulting values (wild-type and Hoxa2 null of E12.5, E13.5, E14.5, E15.5) 
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were then normalized to the E12.5 wild-type sample of that blot. Due to 
differences in the IDV values between different blots it was necessary to 
normalize each blot to a band on its own gel to accurately represent any 
changes in protein expression observed. A total of four blots (n = 4) were 
analyzed using two way ANOVA to compare Six2 protein expression in wild-
type and Hoxa2 null samples at (E12.5, E13.5, E14.5 and E15.5). 
 
5.8 Culturing MEPM cells 
Mouse embryonic palate mesenchyme (MEPM) cells were cultured as 
previously described by Iwata et al., 2012. Briefly, timed pregnant C57 black 
mice were sacrificed at stage E13.5 and their embryos removed.  Palatal 
shelves were aseptically excised from the embryo and placed in Hank’s 
balanced salt solution. A piece of tissue was also taken from the embryo for 
PCR genotyping analysis. In addition, the palatal shelves were treated 
according to Tyler et al., 1980, to separate the palatal mesenchyme from the 
epithelium. Purified palatal mesenchyme was incubated with 0.25% 
trypsin/0.02% EDTA in Ca++-Mg++ free PBS for 20 min at 37°C to dissociate 
individual cells. The digested samples were then briefly triturated and filtered 
through a 70 m mesh. The action of trypsin was terminated using 4°C 
Dulbecco’s Modified Eagle’s Medium (DMEM)/Ham’s medium F12 (1:1) 
containing 10% fetal bovine serum (FBS) supplemented with 1% 
penicillin/streptomycin, L-glutamate, sodium pyruvate and non-essential 
amino acids. The cell number was determined using the MOXI Z automated cell 
counter (Orflo Technologies) and the primary culture of MEPM cells was 
initiated by seeding 5x105 cells/5ml of complete DMEM/F-12 media in a 25ml 
tissue culture flask. Cells were sub cultured at a ratio of 1:3 after achieving 
confluence in a 95% air and 5% CO2 atmosphere. 
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5.9  siRNA treatment and cell proliferation analysis 
The siRNA used was the pre-designed Six2 Silencer Select siRNA 
(Invitrogen: catalogue number 4390771), together with a Silencer select 
negative control siRNA (Invitrogen). siRNA aliquots were prepared by diluting 
the stock siRNA (5nM lyophilized powder) using nuclease-free sterile water 
(Invitrogen) to achieve a working concentration of 20M. MEPM cells (5.0x103) 
were plated in a 96-well plate until they reached 60%-80% confluence. The 
siRNA sample was mixed with lipofectamine 3000 (Invitrogen) according to the 
manufacturer’s protocol. Briefly, for each transfection, 0.3l of lipofectamine 
3000 (Invitrogen) was diluted with 5l of serum free DMEM/F12 media and 
kept at RTM for 5 min. This was mixed with 5l of serum free media containing 
0.25l of siRNA and the mixture vortexed for 10 sec and left at RTM for 20 min. 
Prior to transfection, cells were rinsed twice with serum free media. The above 
siRNA-lipofectamine complex (10l) was added to each well of MEPM cells 
containing 100l of serum free media. Following incubation at 37°C for 12 h, 
the transfection media was replaced with fresh complete media. 
MEPM cells were analyzed for cellular DNA content 48 h from the time of 
transfection using the CyQUANT NF cell proliferation assay kit (Life 
Technologies). The cell proliferation assay was performed as per the 
manufacturer’s protocol. Briefly, the transfected MEPM cells were incubated 
with 1X dye binding solution at 37°C for 45 min in the dark. Fluorescence was 
detected with a microplate reader (BioTek) with excitation at 485nm and 
emission at 530nm.   
 
 
 
41 
 
5.10 Statistical analysis 
All statistical analyses and graphs were performed using the GraphPad 
5.0 software package (GraphPad Prism). Statistical analysis on quantitative real 
time RT-PCR data for Six2 expression was evaluated using two-way analysis of 
variance (2 way ANOVA) followed by Bonferroni post-hoc tests to compare 
between the genotypes and embryonic stages. 
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6. RESULTS 
6.1 Six2 protein exhibits a temporal distribution pattern in the developing 
secondary palate 
In order to investigate if Six2 might be involved in palatogenesis, I first 
examined whether this gene was endogenously expressed during the different 
stages of palatogenesis: emergence and vertical outgrowth of palatal shelves 
(E12.5-E13.5); palatal shelf elevation and horizontal growth (E14.0-E14.5); and 
palatal shelf fusion (E15.0-E15.5). I utilized fluorescence 
immunohistochemistry (IHC) to demonstrate that Six2 protein is expressed 
differentially across the four stages of secondary palate development (E12.5, 
E13.5, E14.5, E15.5). Immunohistochemical analysis of coronal sections from 
the anterior, medial and posterior regions of wild-type embryos showed that 
Six2 protein was initially high at E12.5, increased to peak expression at E13.5 
and reduced at E14.5 before further declining at E15.5 (Fig. 9).  
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Figure 9: Six2 protein exhibits a temporal distribution pattern in the 
developing palate. Immunohistochemical staining of coronal sections from the 
anterior, medial and posterior regions of wild type embryos showing more 
staining of Six2 protein at earlier stages of palatogenesis (E12.5-E13.5) and less 
staining at the later stages (E14.5-E15.5). Panels D, H, I, P are control sections 
where only the secondary antibody was used. Anterior, medial, posterior and 
control sections are all from the same embryo. Arrow indicates epithelium, T-
tongue, M-mesenchyme, 10X magnification.  (scale bar, 10 μm).  
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6.2 Six2 protein is spatially distributed in both the epithelium and 
mesenchyme of the developing secondary palate 
Immunohistochemical analyses of the anterior, medial and posterior 
sections from both wild-type and Hoxa2 knock out embryos revealed that Six2 
protein was consistently expressed in both the epithelium and mesenchyme of 
mouse palatal shelves across the stages of palatogenesis. It was interesting to 
note that Six2 protein was expressed in the nasal palatal epithelium (Fig. 10B) 
but was completely absent from the oral palatal epithelium (Fig. 10D). This 
expression pattern was consistent in the A-P axis of the palate and across the 
stages of secondary palate development. To confirm this finding, I double-
labelled palatal sections by IHC using Six2 and E-cadherin antibodies. E-
cadherin is a known epithelial marker that stains only in the epithelium. Cells in 
the nasal palatal epithelium were positive for both Six2 and E-cadherin staining 
(Fig. 10J), while cells in the oral palatal epithelium were only positive for E-
cadherin (Fig. 10L). This confirmed my earlier observation that Six2 protein was 
only expressed in the nasal palatal epithelium and was completely absent from 
the oral palatal epithelium.  
Furthermore, I observed more Six2 protein expression in the oral half of 
the palatal mesenchyme as compared to the nasal half of the palate 
mesenchyme (Fig. 11). This pattern of expression was again consistent in the A-
P axis of the palate and from E12.5 to E14.5. At E15.5 however, Six2 protein 
expression seemed to be concentrated in the central portions of the palatal 
mesenchyme when compared to the oral and nasal halves of the palatal 
mesenchyme where expression was less. 
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Figure 10: Six2 protein exhibits a spatial expression pattern in the palate 
epithelium. Immunohistochemical double-labelling of Six2 protein (A,B,C,D) 
and of E-cadherin (E,F,G,H) on coronal sections of the developing palate at 
E14.5. Staining of Six2 protein can be observed in the nasal epithelium (B), 
reduced staining in the region of the midline epithelial seam (MES) (C) and no 
staining in the oral epithelium (D). Blue boxes in panels A, E represent 
magnified regions (40X) for the MES, nasal and oral epithelium as shown in 
panels B,C,D,F,G,H,J,K & L . Sections I,J,K,L are overlays. (Scale bar, 10μm). 
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Figure 11: Six2 protein exhibits a spatial expression pattern in the palatal 
mesenchyme. Immunohistochemical staining of representative coronal 
sections of the developing secondary palate of wild-type embryos (E12.5-
E15.5). From E12.5 to E14.5, there is more staining for Six2 protein in the oral 
half of the palatal mesenchyme (arrows) and less staining in the nasal half of 
the palatal mesenchyme (asterisks) (A-C). At E15.5, Six2 protein expression is 
concentrated in the central portions of the palatal mesenchyme (arrows) (D). 
T-tongue.(10x Magnification) (Scale bar, 10μm).  
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6.3 Six2 protein exhibits an A-P differential expression pattern in the 
developing secondary palate 
Analysis of the anterior, medial and posterior regions of the palatal 
epithelium and mesenchyme revealed a differential expression pattern of Six2 
protein in the A-P axis in both the wild-type and Hoxa2 null embryos.  In vivo 
cell counting analysis revealed a general increase in the A-P direction of the 
number of palate mesenchymal cells expressing Six2 protein, with the least 
expression in the anterior and most expression in the posterior regions of the 
palate (Fig. 12A).  
In addition, IHC analysis showed increasing Six2 protein expression in the 
A-P direction with the most expression observed in the posterior portions of 
the palate mesenchyme (Fig. 12B). This expression pattern was consistent for 
both wild-type and Hoxa2 null embryos and across the stages of secondary 
palate development. Also interestingly, it seems that Six2 protein is primarily 
expressed in the anterior nasal palatal epithelium and it progressively 
decreases as one moves into the posterior regions where little or no 
expression is seen in the posterior nasal palatal epithelia (Fig. 12B).  
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B) 
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Figure 12: Six2 protein exhibits an Anterior-Posterior differential expression 
pattern in the palate epithelium and mesenchyme.  
A) In vivo cell counting  analysis of Six2 protein positive cells from 
coronal anterior, medial and posterior sections of wild-type and Hoxa2 null 
mice (E13.5) showing highest Six2 protein expression in the posterior region of 
the palatal mesenchyme of Hoxa2 null embryos.  
B)   Representative coronal sections from the anterior, medial and 
posterior regions of wild type embryos (E13.5) showing Six2 protein expression 
the palatal mesenchyme increasing from the anterior towards the posterior 
region of the secondary palate. It is interesting to observe that in the posterior 
regions, expression of Six2 in the nasal palatal  epithelium is also much lower 
compared to the anterior and medial epithelia. This pattern of expression is 
observed across all stages of palatogenesis and in both wild-type and Hoxa2 
null mice. Six2 positive cells were expressed as a percentage of the total cell 
number (DAPI positive cells). Bars represent mean ± SEM, n=4, *p<0.05, 
**p<0.01. T-tongue. (scale bar,10 μm).  
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6.4 Six2 protein and mRNA are up-regulated in the absence of Hoxa2  
The Hoxa2 gene has been reported to bind to the Six2 promoter in vivo 
to repress its expression (Kujetova et al., 2008). To confirm these findings, I 
performed quantitative real time PCR (qPCR) and western blot analysis on 
palatal shelves from both wild-type and Hoxa2 null embryos. There was a 
significant increase in the expression of Six2 at both the mRNA and protein 
level in the Hoxa2 null embryos when compared to their wild-type littermates 
at all stages of palatogenesis, with peak expression occurring at E13.5 (Figs. 
13B, C). The peak expression of Six2 at E13.5 coincides with the time of palatal 
shelf vertical outgrowth on either sides of the tongue. In addition, I also 
performed absolute mRNA quantification by droplet digital PCR (ddPCR) to 
compare between ddPCR and qPCR  (Appendix Fig.1 ). The results for mRNA 
quantification using ddPCR and qPCR matched indicating consistency of results 
using the two different techniques (Fig.13C and Appendix Fig.1).  
Furthermore, IHC analyses of anterior, medial and posterior sections of 
both wild-type and Hoxa2 null embryos across the stages of palatogenesis 
revealed more Six2 protein expression in the Hoxa2 null embryos compared to 
their wild type littermates (Fig. 13A). Additionally, in vivo cell counting analysis 
of Six2 protein positive cells in the nasal half of the palatal mesenchyme in 
wild-type and Hoxa2 null littermates revealed an expanded domain of Six2 
protein expression in the Hoxa2 null palatal shelves. In the wild-type palatal 
shelves, Six2 protein expression is seen mainly in the oral half of the palatal 
mesenchyme with less expression observed in the nasal half of the palatal 
mesenchyme. In the Hoxa2 null palatal shelves however, the domain of Six2 
protein expression expands from the oral half of the palatal mesenchyme to 
include the nasal half of the palatal mesenchyme (Fig. 14). 
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Figure 13: Six2 mRNA  and protein are up-regulated in the absence  Hoxa2.  
A) The domain of Six2 protein expression is expanded in the Hoxa2 null 
palatal shelves. Immunohistochemical staining of representative medial 
coronal sections of the secondary palate from wild-type and Hoxa2 null 
littermates showing an extended domain of mesenchymal Six2 protein 
expression in the Hoxa2 null palatal shelves (E, F, G, H) compared to wild type 
palatal shelves (A, B, C, D). In the Hoxa2 null palatal shelves, the domain of Six2 
expression expands from the oral half of the palatal mesenchyme to include 
the nasal half of the palatal mesenchyme.  Also, the palatal shelves fail to 
elevate above the tongue at E14.5 and E15.5 in the Hoxa2 null embryos. T-
tongue. (scale bar, 10μm).  
B) Western blot analysis of protein obtained from palatal shelves of wild-
type and Hoxa2 null mice. There is enhanced Six2 protein expression in the 
absence of Hoxa2 across all stages of palatogenesis with peak expression 
occurring at E13.5 in both wild-type and Hoxa2 null palatal shelves.  
C) Relative quantitative expression of Six2 mRNA during murine 
palatogenesis in wild-type and Hoxa2 null mice. In the wild type mice, Six2 
mRNA expression is comparably high at E12.5 and E13.5 and reduces at E14.5 
before decreasing further at E15.5. In the Hoxa2 null mice, expression is 
enhanced across all stages of palatogenesis. In the absence of Hoxa2, Six2 
mRNA is initially high at E12.5 and increases to a peak level at E13.5. This 
expression dramatically reduces at E14.5 before decreasing further at E15.5. 
Bars represent mean ± SEM, n=5, *p<0.05, **p<0.01.  
 
 
 
 
 
 
 
 
 
 
 
53 
 
 
 
 
 
Figure 14: In vivo cell counting analysis of Six2 protein positive cells in the 
nasal half of the palatal mesenchyme in wild-type and Hoxa2 null littermates 
(E14.5) showing an expanded domain of Six2 protein expression in the Hoxa2 
null palatal shelves. In the wild-type palatal shelves, Six2 protein expression is 
seen mainly in the oral half of the palatal mesenchyme with less expression 
observed in the nasal half of the palatal mesenchyme. In the Hoxa2 null palatal 
shelves however, the domain of Six2 protein expression expands from the oral 
half of the palatal mesenchyme to include the nasal half of the palatal 
mesenchyme. Six2 positive cells were expressed as a percentage of the total 
cell number (DAPI positive cells). Bars represent mean ± SEM, n=4, *p<0.05, 
**p<0.01. 
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6.5 Analysis of cell proliferation in vivo 
To investigate whether Six2 has a role to play during palatal 
mesenchyme cell proliferation, I performed IHC analyses on anterior, medial 
and posterior palatal sections of both wild-type and Hoxa2 null embryos, using 
an antibody for the Ki-67 antigen, a known marker of cell proliferation. This 
involved counting cells in a whole palatal shelf including; the total number of 
cells (DAPI positive cells), cells expressing the Six2 protein (Six2 positive cells), 
actively proliferating cells (Ki-67 positive cells) and the cells that were actively 
proliferating and co-expressing the Six2 protein (cells positive for both Six2 and 
ki-67). I chose to investigate this putative role of Six2 at embryonic stage (E) 
13.5 when the palatal shelves start growing vertically downwards on either 
side of the tongue. Incidentally, this is also the stage where I observed peak 
expression of the Six2 gene at both the mRNA and protein level (see Figs. 13A, 
B, C).  
I observed a significant increase in cell proliferation in the Hoxa2 null 
palatal shelves as compared to the wild-type palatal shelves in both the A-P 
axis and the O-N axis of the palatal mesenchyme, with the highest percentage 
of proliferating cells observed in the nasal half of the posterior palatal 
mesenchyme (Figs. 15A-G). In addition, the percentage of proliferating cells 
that were also expressing the Six2 protein (Six2/ki-67 double positive cells) was 
significantly increased in the Hoxa2 null palatal shelves when compared to the 
palatal shelves from wild-type embryos, in both the A-P axis and the O-N axis 
of the palate mesenchyme. Again, the highest percentage of these double 
positive cells was observed in the nasal half of the posterior palatal 
mesenchyme (Figs. 16A-G).  
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Figure 15: Increased cell proliferation in nasal half of the posterior palatal 
mesenchyme of Hoxa2 null palatal shelves.  
A) Immunohistochemical staining of coronal sections from the anterior, medial 
and posterior regions of wild-type and Hoxa2 null palatal shelves (E13.5) for Ki-
67, a marker of cell proliferation. (A-G) In the Hoxa2 null palatal shelves, there 
is a significant increase in cell proliferation in the both the A-P axis and O-N 
axis, with the highest percentage of proliferating cells observed in the nasal 
half of the posterior palatal mesenchyme. Asterisks indicate the nasal half of 
the palatal mesenchyme. Proliferating cells were expressed as a percentage of 
the total cell number (DAPI positive cells). (scale bar,10 μm). Bars represent 
mean ± SEM, n=4, *p<0.05, **p<0.01.  
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Figure 16: The number of cells co-expressing Six2 and Ki-67 is highest in the 
nasal half of the posterior palatal mesenchyme of Hoxa2 null palatal shelves. 
A) Immunohistochemical staining of coronal sections from the anterior, medial 
and posterior regions of wild-type and Hoxa2 null palatal shelves (E13.5) for 
both Six2 and Ki-67 (double staining). (A-G) There is a significant increase in the 
percentage of proliferating cells that are co-expressing Six2 protein (Six2/Ki-67 
double positive cells) in the Hoxa2 null palatal shelves in both the A-P and O-N 
axes of the palatal mesenchyme.  The highest percentage of these double 
positive cells was observed in the in the nasal half of the posterior palatal 
mesenchyme. Asterisks indicate the nasal half of the palatal mesenchyme. 
Cells co-expressing Six2 and Ki-67 were expressed as a percentage of total Six2 
positive cells (scale bar,10 μm). Bars represent mean ± SEM, n=4, *p<0.05, 
**p<0.01.  
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6.6 Analysis of cell proliferation in vitro 
In addition to in vivo cell proliferation analysis, I also performed analyses 
of cell proliferation in vitro. This involved knocking down the expression of Six2 
mRNA in primary palatal cell cultures using Six2 siRNA and observing the effect 
this had on cell proliferation and the expression of the cell cycle regulator, 
Cyclin D1.  I used an MEPM cell culture system of both wild-type and Hoxa2 
null cells. These were freshly cultured primary cells prepared from the palate 
mesenchyme of E13.5 embryos, a stage at which palatal shelves grow vertically 
downwards on either sides of the tongue musculature.  
In order to achieve Six2 mRNA knock down in MEPM cells, two Six2 
siRNA sequences were tested namely; sequence 1 and sequence 2. Six2 siRNA 
sequence 1 achieved 90% knockdown of Six2 mRNA while Six2 siRNA sequence 
2 only achieved 30% knockdown of Six2 mRNA (Fig. 17). I therefore chose to 
use Six2 siRNA sequence 1 for my subsequent experiments. 
 In addition, I used the CyQUANT® NF Cell Proliferation Assay Kit             
(Invitrogen) for in vitro analysis of cell proliferation. The CyQUANT® NF assay is 
based on measurement of cellular DNA content via fluorescent dye binding. 
Because cellular DNA content is highly regulated, it is closely proportional to 
cell number. The extent of proliferation was determined by comparing cell 
counts for siRNA treated MEPM cell cultures and the control cell cultures. The 
two controls used in my experiment were the mock control, where there was 
no siRNA treatment and the cell cultures treated with a scramble control siRNA 
from the same vendor (invitrogen) that is known not to cause Six2 mRNA 
knockdown.  
It was interesting to observe that in vitro Six2 siRNA knock down 
restored cell proliferation in the Hoxa2 null MEPM cell cultures to wild-type 
levels (Fig. 18A). In both the wild-type and Hoxa2 null cell cultures, I observed 
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that cell proliferation was significantly reduced when they were treated with 
Six2 siRNA compared to the mock and control siRNA cell cultures.  
Furthermore, my study sought to find out if the knockdown of Six2 in 
vitro would have an effect on the expression of Cyclin D1. Indeed, I found that 
in vitro Six2 siRNA knock down restored Cyclin D1 expression in the Hoxa2 null 
palatal mesenchyme cell cultures to wild-type levels (Fig. 18B). In both the 
wild-type and Hoxa2 null palatal mesenchyme cell cultures, Cyclin D1 
expression was significantly reduced after Six2 siRNA knock down compared to 
the mock and control siRNA treated cell cultures. 
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Figure 17: Six2 siRNA knockdown in MEPM cells. 90% Six2 mRNA knockdown 
was achieved using Six2 siRNA sequence-1 compared to 30% Six2 mRNA 
knockdown using Six2 siRNA sequence-2. Six2 siRNA sequence-1 was therefore 
chosen for the subsequent experiments. Mock treated cell cultures are those 
where there was no siRNA treatment, while the control siRNA cell cultures 
were treated with a scramble control siRNA. Bars represent mean ± SEM, n=4, 
*p<0.05, **p<0.01.  
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Figure 18: A) In vitro Six2 siRNA knock down restored cell proliferation in the 
Hoxa2 null palate mesenchymal cell cultures to wild-type levels. In both the 
wild-type and Hoxa2 null MEPM cell cultures, proliferation was significantly 
reduced when they were treated with Six2 siRNA compared to the mock and 
control siRNA cultures. B) In vitro Six2 siRNA knock down restored Cyclin D1 
expression in the Hoxa2 null palate mesenchymal cell cultures to wild-type 
levels. In both the wild-type and Hoxa2 null MEPM cell cultures, Cyclin D1 
expression was significantly reduced when they were treated with Six2 siRNA 
compared to the mock and control siRNA cultures. Mock treated cell cultures 
are those where there was no siRNA treatment, while the control siRNA cell 
cultures were treated with a scramble control siRNA. Bars represent mean ± 
SEM, n=4, *p<0.05, **p<0.01.  
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During early embryonic development, a number of genes and signalling 
molecules including, Msx1, Bmp4, Fgf10, Barx1 and Ptx1 are expressed in the 
developing secondary palate (Zhang et al., 2002, Yu et al; 2005, Alappat et al., 
2005). In this study, I wanted to determine if in vitro Six2 siRNA knock down in 
MEPM cell cultures would have an effect on the expression of Bmp4, Msx1, 
Barx1 and Ptx1; some of the palatal mesenchyme cell signalling molecules 
expressed during palatogenesis. In vitro Six2 siRNA knock down did not have an 
effect on the expression of the mRNA transcripts of these genes (Fig. 19). 
However, the expression of Bmp4, Barx1 and Ptx1 mRNAs was significantly 
enhanced in the Hoxa2 null palatal mesenchyme cell cultures compared to the 
wild-type cell cultures. In addition, I observed that Msx1 expression was 
significantly reduced in the Hoxa2 null cell cultures compared to the wild-type 
cell cultures.  
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Figure 19: In vitro Six2 siRNA knock-down did not have an effect on the 
expression of Msx1, Bmp4, Barx1 and Ptx1 mRNA transcripts. However, the 
expression of Bmp4, Barx1 and Ptx1 remained higher in the mock-treated 
control Hoxa2 null MEPM cell cultures compared to the mock-treated control 
wild-type cell cultures. Msx1 expression remained significantly reduced in the 
mock-treated control Hoxa2 null cell cultures compared to the mock-treated 
control wild-type cell cultures. Bars represent mean ± SEM, n=4, *p<0.05, 
**p<0.01.  
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7. DISCUSSION 
7.1 Six2 exhibits a temporal-spatial expression profile in the developing 
secondary palate 
In order to study the function of Six2 in the developing secondary palate, 
my study first sought to establish if this gene is expressed in the mouse 
secondary palate. Indeed, Six2 is expressed in the developing SP and my study 
has characterized for the first time the temporal and spatial distribution 
patterns of Six2 in the developing secondary palate.  
Using real time PCR and western blot analysis, I was able to demonstrate 
that Six2 mRNA and protein respectively are expressed in the developing SP 
from the time of palatal shelf emergence at E12.5 to the time of palatal shelf 
fusion at E15.5 (Fig. 13B, C). In addition, fluorescence IHC on coronal sections 
from heads of wild-type mouse embryos revealed Six2 protein expression at all 
the stages of SP development (Fig.9). Six2 expression at both the mRNA and 
protein level was higher during the earlier stages of palatogenesis (E12.5 and 
E13.5) compared to the later stages of palatogenesis (E14.5 and E15.5) (Fig. 9 
and Fig. 13A-C). Six2 expression is initially high at E12.5, it then increases to a 
peak expression at E13.5 before dramatically reducing at E14.5 and further 
declining by the time of palatal shelf fusion at E15.5. It is interesting to note 
that the peak expression of Six2 at E13.5 coincides with the time when the 
paired palatal shelves start to grow vertically downwards on either sides of the 
tongue.  
These findings have expanded on what earlier studies had reported that 
Six2 is expressed in the craniofacial region of developing mouse embryos as 
early as E11.5 (Oliver et al., 1995; Brodbeck et al., 2004; Fogelgren et al., 2008). 
In addition, the high expression of Six2 at the earlier stages of SP development 
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points to the possibility that this gene might be critical during the stages of 
palatal shelf emergence (E12.5) and palatal shelf vertical outgrowth (E13.5). 
The rapid decline of Six2 expression between E14.0 and E15.5 suggests that 
this gene may not be as critical during the later stages of palatogenesis. 
In addition to demonstrating that that there are temporal changes in 
Six2 expression levels during palatogenesis, my study also revealed regional 
differences in the spatial expression pattern of Six2 in the developing SP. 
Fluorescence IHC demonstrated that Six2 protein was present in both the 
palate epithelium and palatal mesenchyme. Whereas Six2 protein is highly 
expressed in the nasal palatal epithelium (Fig. 10B and Fig. 20)), its expression 
is devoid from the oral palatal epithelium (Fig. 10D and Fig. 20). To confirm this 
finding, I utilized IHC double labelling of Six2 and E-cadherin, a known 
epithelial marker. The cells in the nasal palatal epithelium were positive for 
both Six2 and E-cadherin (Fig. 10J), while the cells lining the oral palatal 
epithelium were only positive for E-cadherin (Fig. 10L).  
Interestingly, I observed an opposite pattern of Six2 protein expression 
in the palatal mesenchyme. Six2 protein was highly expressed in the oral half 
of the palatal mesenchyme, while reduced expression was observed in the 
nasal half of the palate mesenchyme (Fig. 11). This pattern of expression was 
consistent across the A-P axis of the palate and from E12.5 to E14.5 (Fig. 11A-C 
and Fig. 20). At E15.5 however, the pattern of Six2 protein expression in the 
mesenchyme seemed to be altered, with expression concentrated in the 
central portions of the fused palate (Fig. 11D).  
Previous studies by different groups have also reported genes that 
exhibit differential expression patterns in the developing SP. Pax9, a gene that 
has been reported to play an important role in regulating epithelial-
mesenchymal interactions during SP development is expressed in both the 
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mesenchyme and posterior palatal epithelium (Yu et al., 2013). Whereas Pax9 
is expressed throughout the O-N axis of the palatal mesenchyme in the 
posterior region, its expression is lower in the oral half than in the nasal half of 
the palatal mesenchyme in the anterior region. Although the reason for this 
complimentary pattern of Six2 protein expression in the palate epithelium and 
mesenchyme is still unclear, it is possible that Six2 could be involved in the 
epithelial-mesenchymal cross-talk that drives palatal shelf outgrowth. 
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Figure 20:  A schematic diagram illustrating the spatial expression pattern of 
Six2 protein in the developing palate at E13.5 and E14.5. Whereas there is 
expression of Six2 protein in the nasal palatal epithelium (block arrows) and 
the oral half of the palatal mesenchyme (OM), there is no expression in the 
oral palatal epithelium (stick arrows) and the nasal half of the palatal 
mesenchyme (NM), T-tongue.  
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7.2 Six2 protein exhibits an A-P differential expression pattern in the 
developing secondary palate. 
The SP may be divided into three regions along the A-P axis namely; the 
anterior, medial and posterior palate.  Various nomenclature systems have 
been used to designate the boundaries of the anterior, medial and posterior 
regions of the SP. When preparing coronal sections for this study, I followed 
the nomenclature of Smith et al., (2013) which defines tissue lying anterior to 
the first molar tooth bud as the anterior palate, tissue lying posterior to the 
first molar tooth bud as the posterior palate, and tissue in the plane of the first 
molar as the medial palate. Anterior, medial and posterior histological sections 
were taken from the same embryo. Using IHC analysis, I was able to 
demonstrate that Six2 protein exhibits an A-P differential expression profile in 
the developing SP. Although I observed a substantial amount of Six2 protein 
expression in the anterior regions of the palate mesenchyme, there appeared 
to be a gradual increase of Six2 protein expression towards the posterior 
regions of the palate mesenchyme. Also interestingly, it seems that Six2 
protein is primarily expressed in the anterior nasal palatal epithelium and it 
progressively decreases along the A-P axis, such that little or no expression is 
seen in the most posterior nasal palatal epithelium (Fig. 12).  
Previous studies have linked gene expression along the A-P axis to their 
functions in secondary palate development. For example, Msx1 is a gene that 
is primarily expressed in the anterior portions of the SP, while Mn1 is 
expressed mostly in the posterior regions of the palate. Whereas mice lacking 
either Msx1 or Mn1 exhibit a complete cleft palate, Msx1 null mice exhibit 
specific cell proliferation defects in the anterior region, while Mn1 null mice 
have growth deficits in only the middle and posterior regions of the palatal 
shelves (Zhang et al., 2002; Lin et al., 2008). 
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A plausible explanation for the disparity in the patterns of Six2 protein 
expression in the epithelium and mesenchyme of the SP along the A-P axis 
could be that in the epithelium, Six2 protein executes most of its functions in 
the anterior portions of the SP while in the palatal mesenchyme, most of its 
functions are performed in the posterior regions of the secondary palate.   
 
7.3 Six2 mRNA and protein are up-regulated in the absence of Hoxa2 
A study by Kujetova et al., (2005) reported Six2 to be an immediate 
downstream target of Hoxa2, a gene that has been found to play a direct role 
in mouse SP development (Smith et al., 2009). There have also been reports 
that the expression of Six2 in the wild-type embryo is restricted to the first 
branchial arch mesenchyme, and that the loss of function of Hoxa2 results in 
an expansion of the domain of Six2 expression in the branchial arches and in 
the mesenchyme and leads to malformations of the middle and external ear. 
This implies that Hoxa2 expression is sufficient to repress expression of Six2 
(Rijli et al., 1993; Kujetova et al., 2005). In my study, I sought to confirm if loss 
of Hoxa2 function indeed alters the expression of Six2 in the developing SP. My 
study utilized samples from palatal shelves of both wild-type and Hoxa2 null 
embryos. Using qPCR and western blot analysis, I was able to demonstrate that 
Six2 mRNA and protein respectively, were consistently up-regulated in the 
absence of Hoxa2, from the time of initial palatal shelf emergence at E12.5, 
through to the time of palatal shelf fusion at E15.5 (Fig. 13B, C). In addition, 
IHC analyses of anterior, medial and posterior palatal sections of both wild-
type and Hoxa2 null embryos across the stages of palatogenesis revealed more 
Six2 protein expression in the Hoxa2 null embryos compared to their wild-type 
littermates (Fig. 13A).  
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Furthermore, in vivo cell counting analysis of Six2 protein positive cells in 
the nasal half of the palatal mesenchyme in wild-type and Hoxa2 null 
littermates revealed an expanded domain of Six2 protein expression in the 
Hoxa2 null palatal shelves. In the wild-type palatal shelves, Six2 protein 
expression was observed mainly in the oral half of the palatal mesenchyme 
with less expression observed in the nasal half of the palatal mesenchyme. In 
the Hoxa2 null palatal shelves however, the domain of Six2 protein expression 
expanded from the oral half of the palatal mesenchyme to include the nasal 
half of the palatal mesenchyme where intense staining for Six2 protein was 
also observed (Figs. 13A, 14, 21). It is interesting to note that unlike the wild-
type palatal shelves, the Hoxa2 null palatal shelves failed to reorient 
themselves above the tongue but remained positioned vertically on either 
sides of the tongue (Fig.13A).  
My findings therefore confirm that indeed, Six2 is an immediate 
downstream target of Hoxa2 and that Hoxa2 expression alone is enough to 
repress the expression of Six2. 
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Figure 21: A schematic diagram demonstrating an expanded domain of 
Six2 protein expression in the mesenchyme of the Hoxa2 null palatal shelf 
at E14.5.  
A) In the wild-type palatal shelves, Six2 protein expression is observed 
mostly in the oral half of the palatal mesenchyme.  
B) In the Hoxa2 null palatal shelves however, the domain of Six2 protein 
expression in the mesenchyme expands to include the nasal half of the 
palatal mesenchyme. Also, unlike the wild-type palatal shelves, the Hoxa2 
null palatal shelves fail to re-orient themselves above the tongue. NE-nasal 
palatal epithelium, OE-oral palatal epithelium, NM-nasal half of palatal 
mesenchyme, OM-oral half of palatal mesenchyme, T-tongue.  
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7.4 Six2 has an impact on palate mesenchymal cell proliferation during 
palatogenesis 
7.4.1 There is increased cell proliferation and a higher percentage of cells co-
expressing Six2 and Ki-67 in the nasal half of the posterior palatal 
mesenchyme of Hoxa2 null palatal shelves. 
Six2 has been reported to be an immediate downstream target of Hoxa2 
and is up-regulated in Hoxa2 null embryos (Santagati et al., 2005). In addition, 
a study by Smith et al., (2009) reported altered cell proliferation in Hoxa2 null 
palatal shelves. My study therefore sought to investigate if the altered cell 
proliferation observed in the Hoxa2 null palatal shelves is due to the up-
regulation of Six2. 
 In order to investigate this potential role for Six2 during palate 
mesenchymal cell proliferation, I performed IHC analyses on anterior, medial 
and posterior coronal palatal sections of both wild-type and Hoxa2 null 
embryos, using an antibody for the Ki-67 antigen which is a known marker of 
proliferating cells. I had initially wanted to use BrDU as opposed to Ki-67 but I 
encountered technical difficulties in double-labelling Six2 and BrDU. I 
performed a cell counting analysis on whole palatal shelves and also the oral 
and nasal halves of the palatal mesenchyme. The cells counted included the 
total number of cells (Dapi positive cells), cells expressing Six2 protein (Six2 
positive cells), actively proliferating cells (Ki-67 positive cells) and cells that 
were actively proliferating and co-expressing Six2 protein (cells positive for 
both Six2 and Ki-67). I chose to investigate this putative role of Six2 at stage 
E13.5 because this is the stage at which Six2 expression is highest at both the 
mRNA and protein level. Incidentally, this is also the stage when the palatal 
shelves start to grow vertically downwards on either sides of the tongue. Cell 
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counting analysis on whole palatal shelves after Ki-67 staining revealed a 
significant increase in cell proliferation in the Hoxa2 null palatal shelves 
compared to the wild-type palatal shelves in both the A-P and O-N axes of the 
palatal mesenchyme, with the highest percentage of proliferating cells 
observed in the nasal half of the posterior palatal mesenchyme of Hoxa2 null 
palatal shelves (Fig. 15). This finding is in agreement with that of Smith et al., 
(2009) who also observed increased cell proliferation in the Hoxa2 null palatal 
shelves.  
Furthermore, I found that the percentage of actively proliferating cells 
that were co-expressing Six2 (Six2/Ki-67 double positive cells) was significantly 
increased in the Hoxa2 null palatal shelves when compared to palatal shelves 
from wild-type embryos in both the A-P and O-N axes of the palatal 
mesenchyme, with the highest percentage of these double positive cells 
observed in the nasal half of the posterior palatal mesenchyme of Hoxa2 null 
palatal  shelves (Fig. 16).  
As mentioned earlier, I observed Six2 protein expression exclusively in 
the nasal half of the palatal epithelium. In addition, I demonstrated that Six2 
mRNA and protein are up-regulated in the absence of Hoxa2 and that Six2 
protein expression is highest in the posterior regions of the secondary palate. 
These observations, coupled with the fact that I noticed increased cell 
proliferation and the highest percentage of actively proliferating cells that 
were co-expressing Six2 in the nasal half of the posterior palatal mesenchyme 
of Hoxa2 null palatal shelves suggests a potential role for Six2 during the palate 
epithelial-mesenchymal crosstalk that drives palate mesenchymal cell 
proliferation and palatal shelf outgrowth. 
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7.4.2 In vitro Six2 siRNA knockdown restored cell proliferation and Cyclin D1 
expression in Hoxa2 null MEPM cell cultures to wild-type levels 
In order to further investigate the role of Six2 in palate mesenchymal cell 
proliferation, I performed in vitro Six2 siRNA knockdown in MEPM primary cells 
obtained from palatal shelves of both wild-type and Hoxa2 null mouse 
embryos. The palatal shelves were harvested at E13.5 when Six2 expression is 
at its peak. I mentioned earlier that my study has confirmed previous reports 
that there is increased palate mesenchymal cell proliferation in Hoxa2 null 
palatal shelves compared to wild-type palatal shelves. In addition, my study 
reveals enhanced Six2 expression in the absence of Hoxa2. It was therefore 
interesting to discover that in vitro Six2 siRNA knockdown restored palate 
mesenchymal cell proliferation in the Hoxa2 null MEPM cell cultures to wild-
type levels (Fig. 18A). This finding points to the possibility that the increased 
cell proliferation observed after knocking out Hoxa2, could in part, be due to 
enhanced Six2 expression. Zhang et al., (2002) and Rice et al., (2004) found 
that exogenous application of Shh induced a mitogenic response in palatal 
explants cultures mediated in part by the cell cycle regulators Cyclin D1 and 
Cyclin D2. In this study, I found that in vitro Six2 siRNA knockdown also 
restored Cyclin D1 expression in the Hoxa2 null MEPM cell cultures to wild-
type levels (Fig. 18B). This implies that the cell cycle regulator Cyclin D1 is 
acting downstream of Six2 in the palate mesenchyme. This finding re-affirmed 
my initial suspicions that Six2 might play a crucial role in palate mesenchymal 
cell proliferation.  
My study further investigated if in vitro Six2 siRNA knock down had an 
effect on the expression of Msx1, Bmp4, Barx1 and Ptx1, some of the genes 
involved in palate mesenchymal cell signalling during SP development (Smith 
74 
 
et al., 2009). In vitro Six2 siRNA knockdown however, did not alter the 
expression of any of the above mentioned genes (Fig. 19). A possible 
explanation for this observation could be that these genes are acting upstream 
of Six2 in the mesenchyme during SP development. Collectively, the ability of 
actively proliferating palate mesenchymal cells to co-express Six2 protein and 
the restoration of palate mesenchymal cell proliferation and Cyclin D1 
expression in Hoxa2 null MEPM cell cultures to wild-type levels points to the 
possibility that Six2 might have a role to play in palate mesenchymal cell 
proliferation. In addition, this finding has confirmed the cell cycle regulator 
Cyclin D1 as a putative downstream target of Six2 in the palate mesenchyme. 
 
 
 
 
 
 
 
 
 
 
 
 
75 
 
8. CONCLUSION 
Although Six2 has been widely studied in mammalian embryonic 
development, its precise role during mammalian secondary palate 
development has never been reported. My study reveals for the first time that 
Six2 is expressed during all stages of secondary palate development with peak 
expression occurring at E13.5 at both the mRNA and protein level. My results 
also show that Six2 protein is expressed in the nasal palatal epithelium but is 
completely absent from the oral palatal epithelium. In addition, I observed 
increased staining for Six2 protein in the oral half of the palatal mesenchyme 
and reduced staining for Six2 protein in the nasal half of the palatal 
mesenchyme. My study also demonstrates that Six2 protein exhibits an A-P 
differential expression pattern in the developing SP. Six2 protein expression in 
the palatal mesenchyme increases in the anterior to posterior direction with 
the most expression observed in the posterior regions of the palate. On the 
contrary, Six2 protein expression in the nasal palatal epithelium seems to 
decrease as one moves from the anterior regions of the palate to the posterior 
regions of the palate.  
Furthermore, I show that Six2 is up-regulated in the absence of Hoxa2 at 
both the mRNA and protein level, consistent with earlier reports that Hoxa2 
binds to the Six2 promoter in vivo to repress its expression. I also successfully 
demonstrated that actively proliferating palate mesenchymal cells were co-
expressing Six2 protein, indicating a potential role for Six2 during palate 
mesenchymal cell proliferation. This finding was further strengthened by in 
vitro studies on primary MEPM cell cultures which showed that in vitro Six2 
siRNA knockdown restored cell proliferation and Cyclin D1 expression in the 
Hoxa2 null MEPM cell cultures to wild type levels.  
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Collectively, my data reveals a novel expression profile for Six2 in the 
developing murine SP and suggests a possible role it might play during the 
epithelial-mesenchymal crosstalk that drives palatal shelf cell proliferation and 
outgrowth.   
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9. FUTURE WORK CONSIDERATIONS 
My study sought to find out if Six2 is expressed in the developing murine 
SP, and if it is, what role it might be playing during SP development. Although I 
can confidently state that all the experimental objectives of my thesis project 
were met, my study raises at least as many questions as it has answered. My 
data reveals a detailed expression analysis of Six2 in the developing SP. Using 
qPCR and Western blot analyses, I demonstrate that Six2 is expressed across all 
stages of SP development, while IHC reveals the spatial expression profile of 
this gene product in both the epithelium and mesenchyme of the developing 
palate. However, studies on precise Six2 mRNA localization need to be 
conducted so as to consolidate the findings of this study in regard to 
expression analysis. This can be conducted by in situ hybridization studies with 
use of palatal tissue sections or whole mount in situ hybridization.                       
I have also shown that Six2 is mostly expressed during the earlier stages of SP 
development (E12.5-E13.5), suggesting that it might perform most of its 
functions at this earlier stage. In this study, in vitro cell proliferation analysis 
using MEPM cells showed that siRNA knockdown of Six2 in Hoxa2 null cells 
restored cell proliferation and Cyclin D1 expression to wild type levels. This 
finding could be strengthened by using the palatal shelves of a Six2 knock out 
mouse model instead of MEPM cell cultures. It would also be interesting to 
find out if the Six2 knockout mouse has any defects in palate morphology. In 
addition, in vivo cell counting analysis using a cell proliferation marker such as 
Ki-67 or Brdu could be performed on coronal palate sections to directly 
compare cell proliferation in the Six2 null and wild-type mice. Also, a 
Six2/Hoxa2 double knock out mouse model could shed more light on the 
restoration to wild-type levels of cell proliferation and expression of cell cycle 
regulators such as Cyclin D1 and Cyclin D2. A study can also be designed to 
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investigate if epithelial specific inactivation of Six2 (by silencing Six2 in palatal 
epithelial cell cultures) could have an effect on palate mesenchymal cell 
proliferation.                                                                                                    
Furthermore, the palatal cell signalling pathways that Six2 might be involved in 
are yet to be studied. The Shh signalling pathway is of particular interest 
because this gene is expressed in the oral palatal epithelium while Six2 is also 
highly expressed in the oral half of the underlying palate mesenchyme. It is 
therefore possible that epithelial-mesenchymal interactions exist between Shh 
in the epithelium and Six2 in the underlying mesenchyme. In addition, previous 
studies have revealed that the expression of Osr1 and Osr2, which are some of 
the genes that are exclusively expressed in the oral half of the palatal 
mesenchyme is dependent on Shh signalling (Fig. 22). It would therefore be 
interesting to investigate if a linkage exists between Shh, Six2, Osr1 and Osr2.   
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Figure 22: A schematic illustration of the pathways involved in O-N 
patterning during palatal shelf out growth.  
Whereas Pax9 is expressed across the O-N axis of the posterior palatal 
mesenchyme, it is expressed at higher levels in the nasal half of the palatal 
mesenchyme than in the oral half of the palatal mesenchyme in the anterior 
regions of the palate. In addition, Pax9 has been reported to have inhibitory 
effects on both Osr2 and Fgf10 in the palate mesenchyme. Fgf10 is exclusively 
expressed in the oral half of the palatal mesenchyme. Six2 also exhibits a 
graded pattern of expression in the palate mesenchyme with higher expression 
in the oral half of the palate mesenchyme than in the nasal half of the palate 
mesenchyme. Six2 is highly expressed in the nasal palate epithelium but is 
devoid from the oral palatal epithelium. Hoxa2 has been reported to have 
inhibitory effects on Six2 expression. Whereas Osr1 expression is limited to the 
oral half of the palate mesenchyme, Osr2 is expressed at high levels in the oral 
half of the palatal mesenchyme than in the nasal half. Expression of both Osr1 
and Osr2 is dependent on Shh signalling. Also, a pathway involving Dlx5-Fgf7 
signalling acts as a repressor of Shh signalling and controls outgrowth along the 
ON axis. The dotted line denotes the O-N boundary of the palatal 
mesenchyme. Nasal palatal epithelium (NE), Nasal half of the palatal 
mesenchyme (NM), Oral palatal epithelium (OE), Oral half of the palatal 
mesenchyme (OM), Tongue (T). Arrows indicate inductive relationships, solid 
lines represent direct physical interaction while blunt arrows indicate 
inhibitory effects. Purple boxes indicate expression in the oral half of the 
palate mesenchyme while orange boxes indicate expression in the nasal half of 
the palate mesenchyme. The size of the boxes is directly proportional to the 
extent of expression in the epithelium and the oral or nasal half of the palate 
mesenchyme. 
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Pax9 has been reported to have an inhibitory effect on the expression of 
both Fgf10 and Osr2. Pax9 mRNA has been reported to be preferentially 
expressed in the nasal half of the palatal mesenchyme in the anterior palate. 
Incidentally, my study shows that Six2 is present only in the nasal palatal 
epithelium and that there are more actively proliferating cells that co-express 
Six2 in the nasal half of the palate mesenchyme. Additional studies therefore 
can be conducted to reveal the relationship between Six2, Pax9, Osr2 and 
Fgf10 in the nasal half of the palate mesenchyme. Fgf7 and Dlx5 are the other 
genes that have been found to be expressed spatially and temporally in the 
developing palate. Additionally, tissue specific inactivation of Six2 in either the 
epithelium or mesenchyme of the palate can be used to find out if Six2 is 
acting upstream of any of these genes to regulate their expression. This study 
also reported that the knock down of Six2 in MEPM cells did not have an effect 
on the expression of Bmp4, Msx1, Barx1 and Ptx1. This could be because these 
genes might be acting up stream of Six2. Further investigations using 
Chromatin immunoprecipitation (ChIP) analysis can be performed to confirm 
whether these genes are indeed acting upstream to regulate Six2 expression. 
 
 
 
 
 
 
 
 
 
81 
 
10. REFERENCES 
 Alappat, S. R., Zhang, Z., Suzuki, K., Zhang, X., Liu, H., Jiang, R., Yamada, 
G. and Chen, Y. P. (2005). The cellular and molecular etiology of the cleft 
secondary palate in Fgf10 mutant mice. Dev. Biol. 277: 102-113. 
 Alwazzan M, Newman E, Hamshere MG, Brook JD, (1999). Myotonic 
dystrophy is associated with a reduced level of RNA from the DMWD 
allele adjacent to the expanded repeat. Hum. Mol. Genet. 8:1491-1497. 
 Baek, J. A., Lan, Y., Liu, H., Maltby, K. M., Mishina, Y. and Jiang, R. (2011). 
Bmpr1a signaling plays critical roles in palatal shelf growth and palatal 
bone formation. Dev. Biol, 350, 520-531. 
 Barlow, A. J., Bogardi, J. P., Ladher, R. and Francis-West, P. H. (1999). 
Expression of chick Barx-1 and its differential regulation by FGF-8 and 
BMP signaling in the maxillary primordia. Dev. Dyn, 214, 291-302. 
 Belloni, E., Muenke, M., Roessler, E., Traverso, G., Siegel-Bartelt, J., 
Frumkin, A., Mitchell, H. F., Donis-Keller, H., Helms, C., Hing, A. V. (1996). 
Identification of Sonic hedgehog as a candidate gene responsible for 
holoprosencephaly. Nat. Genet. 14: 353-356. 
 Boucher CA, King SK, Carey N, Krahe R, Winchester CL, Rahman S, 
Crearin T, Meghji P, Bailey MES, Chartier FL, Brown SD, Siciliano MJ, 
Johnson KJ, (1995). A novel homeodomain-encoding gene is associated 
with a large CpG island interrupted by the myotonic dystrophy unstable 
CTG repeat. Hum. Mol. Genet. 4:1919-1925. 
 Boucher, C., Carey, N., Edwards, Y., Siciliano, M. and Johnson, K. (1996). 
Cloning of the human SIX1 gene and its assignment to chromosome 14. 
Genomics 33: 140-142 
82 
 
 Brodbeck, S., Besesnbeck, B. and Englert, C, (2004). The transcription 
factor Six2 activates expression of the Gdnf gene as well as its own 
promoter. Mech. Dev. 121: 1211-1222. 
 Bronner-Fraser M. (1993). Neural crest cell migration in the developing 
embryo. Trends Cell Biol. 3:392–397. 
 Brown, S. A., Warburton, D., Brown, L. Y., Yu, C. Y., Roeder, E. R., Stengel-
Rutkowski, S., Hennekam, R. C. and Muenke, M. (1998). 
Holoprosencephaly due to mutations in ZIC2, a homologue of Drosophila 
odd-paired. Nat. Genetics 20: 180-183. 
 Bush, J. O. and Jiang, R. (2012). Palatogenesis: morphogenetic and 
molecular mechanisms of secondary palate development. Development 
139, 231-243. 
 Chai, Y. and Maxson, R.E. Jr (2006). Recent advances in craniofacial 
morphogenesis. Dev. Dyn. 235: 2353–2375. 
 Cheyette BNR, Green PJ, Martin K, Garren H, Hartenstein V, Zipursky SL, 
(1994). The Drosophila sine oculis locus encodes a homeodomain-
containing protein required for the development of the entire visual 
system. Neuron. 12:977-996. 
 Christensen, K.L., Patrick, A.N., McCoy, E.L., Ford, H.L., (2008). The Six 
family of homeobox genes in development and cancer. Adv. Cancer Res. 
101: 93–126. 
  Christopher M Hindson, John R Chevillet, Hilary A Briggs, Emily N 
Gallichotte, Ingrid K Ruf, Benjamin J Hindson, Robert L Vessella & 
Muneesh Tewari. (2013). Absolute quantification by droplet digital 
PCRversus analog real-time PCR. nmeth.2633,10.1038. 
 Chu-An Wang, David Drasin, Catherine Pham, Paul Jedlicka, Vadym 
Zaberezhnyy, Michelle Guney, Howard Li, Raphael Nemenoff, James C. 
83 
 
Costello, Aik-Choon Tan and Heide L. Ford. (2014). Homeoprotein Six2 
promotes breast cancer metastasis via transcriptional and epigenetic 
control of E-Cadherin expression. Cancer Res, 74(24): 7357-70. 
 Couly GF, Coltey PM, Le Douarin NM, (1993). The triple origin of skull in 
higher vertebrates — a study in quail-chick chimeras. Development, 
117:409-429. 
 Ferguson,M.W.J, (1998). Palate development. Development.; 
103(Suppl.), 41–60. 
 Fitchett, J. E. and Hay, E. D. (1989). Medial edge epithelium transforms 
to mesenchyme after embryonic palatal shelves fuse. Dev. Biol. 131, 
455-474. 
 Fitzpatrick, D. R., Denhez, F., Kondaiah, P. and Akhurst, R. J. (1990). 
Differential Expression of TGF Beta Isoforms in Murine Palatogenesis. 
Dev. Biol. 109, 585-595. 
 Fogelgren B., Kuroyama MC., McBratney-Owen B., Spence AA., Melahn 
LE., Anawati MK., Cabatbat C., Alarcon VB., Marikawa Y., and Lozanoff S, 
(2008). Misexpression of Six2 is associated with heritable frontonasal 
dysplasia and renal hypoplasia in 3H1 Br mice. Developmental Dynamics; 
237:1767-1779. 
 Fogelgren B., Yang S., Sharp IC., Huckstep OJ., Ma W., Somponpun J., 
Carlson EC., Uyehara CFT., Lozanoff S, (2009). Deficiency in Six2 during 
prenatal development is associated with reduced nephron number, 
chronic renal failure, and hypertension in Br/+ adult mice.  American 
Journal of Physiology (Renal); 296(5):F1166-78.  
 Gallardo ME, Lopez-Rios J, Fernaud-Espinosa I, Granadino B, Sanz R, 
Ramos C, Ayuso C, Seller MJ, Brunner HG, Bovolenta P, de Cordoba SR, 
(1999). Genomic cloning and characterization of the human homeobox 
84 
 
gene Six6 reveals a cluster of Six genes in chromosome 14 and associates 
Six6 hemizygosity with bilateral anophthalmia and pituitary anomalies. 
Genomics; 61:82-91. 
 Gendron-Maguire, M., Mallo, M., Zhang, M. and Gridley, T. (1993). Hoxa-
2 mutant mice exhibit homeotic transformation of skeletal elements 
derived from cranial neuralcrest. Cell, 75:1317-1331. 
 Gong, K.Q., Yallowitz, A.R., Sun, H., Dressler, G.R., Wellik, D.M., (2007). A 
Hox–Eya–Pax complex regulates early kidney developmental gene 
expression. Mol. Cell. Biol, 21:7661–7668. 
 Gorlin, R.J., Cohen, M.M., Jr., and Hennekam, R.C.M. (2001). Syndromes 
of the head and neck. 4th edition.Oxford University Press. New York, 
New York, USA. 850–853. 
 Granadino B, Gallardo ME, Lopez-Rios J et al, (1999): Genomic cloning, 
structure, expression pattern, and chromosomal location of the human 
SIX3 gene. Genomics, 55: 100–105. 
 Griffith, C.M and Hay, E.D.(1992). Epithelial-mesenchymal trans- 
formation during palatal fusion: carboxyfluorescein traces cells at light 
and electron microscopic levels. Development 116, 1087–1099. 
 Gritli-Linde A, (2007). Molecular control of secondary palate 
development. Dev Biol, 301:309-326. 
 Guiyuan He, Sara Tavella, Karen Piper Hanley, Michelle Self, Guillermo 
Oliver, Raphaëlle Grifone, Neil Hanley, Christopher Ward, Nicoletta 
Bobola., (2010). Inactivation of Six2 in mouse identifies a novel genetic 
mechanism controlling development and growth of the cranial base. 
Developmental Biology 344: 720–730. 
 Han, J., Mayo, J., Xu, X., Li, J., Bringas, P., Jr, Maas, R. L., Rubenstein, J. L. 
and Chai, Y. (2009). Indirect modulation of Shh signaling by Dlx5 affects 
85 
 
the oral-nasal patterning of palate and rescues cleft palate in Msx1-null 
mice. Development 136, 4225-4233. 
 Harris S, Moncrieff C, Johnson K, (1996). Myotonic dystrophy: will the 
real gene please step forward! Hum Mol Genet,5:1417±1423. 
 He G, Tavella S, Hanley KP, Self M, Oliver G, Grifone R, Hanley N, Ward C, 
Bobola N, (2010). Inactivation of Six2 in mouse identifies a novel genetic 
mechanism controlling development and growth of the cranial base.  
Dev Biol, 344:720-730.  
 Heath SK, Carne S, Hoyle C Johnson, KJ, Wells DJ, (1997). 
Characterisation of expression of mDMAHP, a homeodomain-encoding 
gene at the murine DM locus. Hum Mol Genet, 6:651±657. 
 Helms JA, Cordero D, Tapadia MD. (2005). New insights into craniofacial 
morphogenesis. Development 132:851–861. 
 Hilliard, S. A., Yu, L., Gu, S., Zhang, Z. and Chen, Y. P. (2005). Regional 
regulation of palatal growth and patterning along the anterior-posterior 
axis in mice. J. Anat. 207, 655-667. 
 Hinrichsen K. (1985). The early development of morphology and 
patterns of the face in the human embryo. Adv Anat Embryol Cell Biol 
98:1–79. 
 Holmes , L.B., Harvey, E.A., Coull B.A., Hunnington, K.B., Khoshbin, S., 
Hayes, A.M., Ryan, L.M. (2001). The teratogenicity of anticonvulsant 
drugs. N Engl JMed. 344, 1132-1138. 
 Hosokawa, R., Deng, X., Takamori, K., Xu, X., Urata, M., Bringas, P., Jr and 
Chai, Y. (2009). Epithelial-specific requirement of FGFR2 signaling during 
tooth and palate development. J. Exp. Zool. B Mol. Dev. Evol. 312, 343-
350. 
86 
 
 Hu D, Helms JA. (1999). The role of sonic hedgehog in normal and 
abnormal craniofacial morphogenesis. Development 126:4873–4884. 
 Hu, M. C., Mo, R., Bhella, S., Wilson, C. W., Chuang, P. T., Hui, C. C. And 
Rosenblum, N. D. (2006). GLI3-dependent transcriptional repression of 
Gli1, Gli2 and kidney patterning genes disrupts renal morphogenesis. 
Development 133, 569-578. 
 Ishibashi, M. and McMahon, A. P. (2002). A sonic hedgehog-dependent 
signaling relay regulates growth of diencephalic and mesencephalic 
primordial in the early mouse embryo. Development 129: 4807-4819. 
 Jing Zhou, Yang Gao, Yu Lan, Shihai Jia and Rulang Jiang. (2013). Pax9 
regulates a molecular network involving Bmp4, Fgf10, Shh signaling and 
the Osr2 transcription factor to control palate morphogenesis. 
Development 140, 4709-4718. 
 Johnston MC, Bronsky PT. 1995. Prenatal craniofacial development: new 
insights on normal and abnormal mechanisms. Crit Rev Oral Biol Med 
6:368–422. 
 Jun-ichi Iwata, Joseph G. Hacia,  Akiko Suzuki, Pedro A. Sanchez-Lara, 
Mark Urata, and Yang Chai.2012. Modulation of noncanonical TGF-β 
signalling prevents cleft palate in Tgfbr2 mutant mice. J Clin Invest, 
22(3):873–885. 
 Kaartinen, V., Cui, X. M., Heisterkamp, N., Groffen, J. and Shuler, C. F. 
(1997). Transforming growth factor-beta 3 regulates transdifferentiation 
of medial edge epithelium during palatal fusion and associated 
degradation of the basement membrane. Dev. Dyn. 209, 255-260. 
 Kaufman MH. (1992). The atlas of mouse development. New York: 
Academic Press. P 1–512. 
87 
 
 Kawakami K, Ohto H, Takizawa T, Saito T, (1996). Identification and 
expression of Six family genes in mouse retina. FEBS Lett, 393:259± 263. 
 Kawakami, K., Sato, S., Ozaki, H. and Ikeda, K. (2000). Six family genes–
structure and function as transcription factors and their roles in 
development. BioEssays 22:  616-626. 
 Kenney, A. M. and Rowitch, D. H. (2000). Sonic hedgehog promotes G(1) 
cyclin expression and sustained cell cycle progression in mammalian 
neuronal precursors. Mol. Cell. Biol. 20: 9055-9067. 
 Kiyoshi Kawakami, Shigeru Sato, Hidenori Ozaki, and Keiko Ikeda, (2000).  
Six family genes-structure and function as transcription factors and their 
roles in development. BioEssays; 22:616-626. 
 Klesert TR, Otten AD, Bird TD, Tapscott SJ, (1997). Trinucleotide repeat 
expansion at the myotonic dystrophy locus reduces expression of 
DMAHP. Nat Genet, 16:402±406. 
 Köntges, G. and Lumsden, A. (1996). Rhombencephalic neural crest 
segmentation is preserved throughout craniofacial ontogeny. 
Development 122: 3229-3242. 
 Kutejova, E., Engist, B., Mallo, M., Kanzler, B. and Bobola, N, (2005). 
Hoxa2 downregulates Six2 in the neural crest derived mesenchyme.  
Development; 132: 469-478. 
 Kutejova, E., Engist, B., Self, M., Oliver, G., Kirilenko, P. and Bobola, N. 
(2008). Six2 functions redundantly immediately downstream of Hoxa2. 
Development 135: 1463-1470. 
 LaBonne C, Bronner-Fraser M. (1999). Molecular mechanisms of neural 
crest formation. Annu Rev Cell Dev Biol 15:81–112. 
88 
 
 Lan, Y. and Jiang, R. (2009). Sonic hedgehog signaling regulates 
reciprocal epithelial-mesenchymal interactions controlling palatal 
outgrowth. Development 136, 1387-1396. 
 Lan, Y., Ovitt, C. E., Cho, E. S., Maltby, K. M., Wang, Q. and Jiang, R. 
(2004). Odd skipped related 2 (Osr2) encodes a key intrinsic regulator of 
secondary palate growth and morphogenesis. Development 131, 3207-
3216. 
 Le Douarin NM, Creuzet S, Couly G, Dupin E. (200)4. Neural crest cell 
plasticity and its limits. Development 131:4637–4650. 
 Li, L., Lin, M., Wang, Y., Cserjesi, P., Chen, Z. and Chen, Y. (2011). BmprIa 
is required in mesenchymal tissue and has limited redundant function 
with BmprIb in tooth and palate development. Dev. Biol. 349, 451-461. 
 Li, Q. and Ding, J. (2007). Gene expression analysis reveals that 
formation of the mouse anterior secondary palate involves recruitment 
of cells from the posterior side. Int. J. Dev. Biol. 51, 167-172. 
 Liu, W., Lan, Y., Pauws, E., Meester-Smoor, M. A., Stanier, P., Zwarthoff, 
E. C. and Jiang, R. (2008). The Mn1 transcription factor acts upstream of 
Tbx22 and preferentially regulates posterior palate growth in mice. 
Development 135, 3959-3968. 
 Liu, W., Sun, X., Braut, A., Mishina, Y., Behringer, R. R., Mina, M. And 
Martin, J. F. (2005). Distinct functions for Bmp signaling in lip and palate 
fusion in mice. Development 132, 1453-1461. 
 Lobjois, V., Benazeraf, B., Bertrand, N., Medevielle, F. and Pituello, F. 
(2004). Specific regulation of Cyclins D1 and D2 by FGF and Shh signaling 
coordinates cell cycle progression, patterning, and differentiation during 
early steps of spinal cord development. Dev. Biol. 273: 195-209. 
89 
 
 Lozanoff S, Johnston J, Ma W, Jourdan-Le Saux C. (2001). 
Immunohistochemical localization of Pax2 and associated proteins in the 
developing kidney of mice with renal hypoplasia. J Histochem Cytochem 
49:1081–1097. 
 Lozanoff S. (1993). Midfacial retrusion in adult Brachyrrhine mice. Acta 
Anat (Basel) 147:125–132. 
 Lumsden A, Keynes R. (1989). Segmental patterns of neuronal 
development in the chick hindbrain. Nature, 337:424-428. 
 Lumsden A, Sprawson N, Graham A. (1991)Segmental origin and 
migration of neural crest cells in the hindbrain region of the chick 
embryo. Development, 113:1281-1291. 
 Lyu Z, Mao Z, Wang H, Fang Y, Chen T, Wan Q, Wang M, Wang N, Xiao J, 
Wei H, Li X, Liu Y and Zhou Q. (2013). MiR-181b targets Six2 and inhibits 
the proliferation of metanephric mesenchymal cells in vitro. Biochem 
BiophysRes Commun, 440(4): 495-501. 
 Ma W, Lozanoff S. (1996). Morphological deficiency in the prenatal 
anterior cranial base of midfacially retrognathic mice. Journal of 
Anatomy, 188:547-555.  
 Ma W, Lozanoff S. (1999). Spatial and temporal distribution of cellular 
proliferation in the cranial base of normal and midfacially retrusive mice. 
Clin Anat 12:315–325. 
 Martı´nez-A´ lvarez, C., Bonelli, R., Tudela, C., Gato, A., Mena, J., O’Kane, 
S., Ferguson, M.W. (2000). Bulging medial edge epithelial cells and 
palatal fusion. Int. J. Dev. Biol. 44:  331– 335. 
 McBratney, B.M., Margaryan, E., Ma, W., Urban, Z. and Lozanoff, S.  
(2003). Frontonasal dysplasia in Br/Br mice. Anatomical Record; 
271A:291-302. 
90 
 
 McMahon, A. P., Ingham, P. W. and Tabin, C. J. (2003). Developmental 
roles and clinical significance of hedgehog signaling. Curr. Top. Dev. Biol. 
53, 1-114. 
 Meng L, Bian Z, Torensma R, Von den Hoff JW. (2009). Biological 
mechanisms in palatogenesis and cleft palate. J Dent Res, 88:22-33. 
 Mill, P., Mo, R., Hu, M. C., Dagnino, L., Rosenblum, N. D. and Hui, C. 
C.(2005). Shh controls epithelial proliferation via independent pathways 
that converge on N-Myc. Dev. Cell 9: 293-303. 
 Mitchell LE. (2009). Epidemiology of cleft lip and palate. In 
Comprehensive Cleft Care. Edited by: Losee JE, Kirschner RE. McGraw-
Hill, Toronto, ON, Canada:35-41. 
 Nawshad A. (2008). Palatal seam disintegration: to die or not to die? that 
is no longer the question. Dev Dynam, 237:2643-2656. 
 Neilson KM, Pignoni F, Yan B, Moody SA. (2010). Developmental 
expression patterns of candidate cofactors for vertebrate six family 
transcription factors. Dev Dyn, 239: 3446-3466. 
 Noden D, (1983)The role of the neural crest in patterning of avian cranial 
skeletal, connective, and muscle tissues. Dev Biol, 96:144-165. 
 Ohto H, Takizawa T, Saito T, Kobayashi M, Ikeda K, Kawakami K. (1998). 
Tissue and developmental distribution of Six family gene products. Int J 
Dev Biol, 42:141±148. 
 Oliver G, Mailhos A, Wehr R et al, 1995). SIX3, a murine homologue of 
the sine oculis gene, demarcates the most anterior border of the 
developing neural plate and is expressed during eye development. 
Development,  121: 4045–4055. 
91 
 
 Oliver, G., Wehr, R., Jenkins, N. A., Copeland, N. G., Cheyette, B. N., 
Hartenstein, V., Zipursky, S. L. and Gruss, P. (1995). Homeobox genes 
and connective tissue patterning. Development, 121: 693-705. 
 Otten AD, Tapscott SJ. (1995). Triplet repeat expansion in myotonic 
dystrophy alters the adjacent chromatin structure. Proc Natl Acad Sci 
USA, 92:5465±5469. 
 Pantalacci, S., Prochazka, J., Martin, A., Rothova, M., Lambert, A., 
Bernard, L., Charles, C., Viriot, L., Peterkova, R. and Laudet, V. (2008). 
Patterning of palatal rugae through sequential addition reveals an 
anterior/posterior boundary in palatal development. BMC Dev. Biol. 8, 
116. 
 Pauws, E., Moore, G. E. and Stanier, P. (2009). A functional haplotype 
variant in the TBX22 promoter is associated with cleft palate and 
ankyloglossia. J. Med. Genet. 46, 555-561. 
 Pelton, R. W., Hogan, B. L., Miller, D. A. and Moses, H. L. (1990). 
Differential Expression of Genes Encoding TGFs Beta 1, Beta 2, and Beta 
3 during Murine Palate Formation. Dev. Biol. 141, 456-460. 
 Peters, H., Neubüser, A., Kratochwil, K. and Balling, R. (1998). Pax9-
deficient mice lack pharyngeal pouch derivatives and teeth and exhibit 
craniofacial and limb abnormalities. Genes Dev. 12, 2735-2747. 
 Rice, R., Connor, E. and Rice, D. P. (2006). Expression patterns of 
Hedgehog signalling pathway members during mouse palate 
development. Gene Expr. Patterns 6, 206-212. 
 Rice, R., Spencer-Dene, B., Connor, E. C., Gritli-Linde, A., McMahon, A. P., 
Dickson, C., Thesleff, I. and Rice, D. P. (2004). Disruption of Fgf10/Fgfr2b 
coordinated epithelial-mesenchymal interactions causes cleft palate. J. 
Clin. Invest.113, 1692-1700.  
92 
 
 Richman JM. (1995). Head development. Craniofacial genetics makes 
headway. Curr Biol, 5:345–8. 
 Rijli FM, Mark M, Lakkaraju S, Dierich A, Dolle´ P, Chambon P. (1993). A 
homeotic transformation is generated in the rostral branchial region of 
the head by disruption of Hoxa2, which acts as a selector gene. Cell 
75:1333–1349. 
 Roessler E, Muenke M. (1998): Holoprosencephaly: a paradigm for the 
complex genetics of brain development. J Inherit Metab Dis, 21: 481–
497. 
 Roessler, E. and Muenke, M. (2003). How a Hedgehog might see 
holoprosencephaly. Hum. Mol. Genet. 12, R15-R25. 
 Santagati F, Minoux M, Ren S-Y, Rijli FM. (2005). Temporal requirement 
of Hoxa2 in cranial neural crest skeletal morphogenesis. Development, 
132:4927–4936. 
 Self, M., Lagutin, O. V., Bowling, B., Hendrix, J., Cai, Y., Dressler, G. R. And 
Oliver,G. (2006). Six2 is required for suppression of nephrogenesis and 
progenitor renewal in the developing kidney. EMBO J, 25: 5214-5228. 
 Selleck M.A. and Bronner-fraser M. (1995). Origins of the avian neural 
crest: the role of neural plate-epidermal interactions. Development, 
121:525-538 
 Seo HC, Curtiss J, Mlodzik M, Fjose A. (1999). Six class homeobox genes 
in drosophila belong to three distinct families and are involved in head 
development. Mech Dev, 83:127±139. 
 Shuler CF. (1995). Programmed cell death and cell transformation in 
craniofacial development. Crit Rev Oral Biol Med, 6:202–17. 
93 
 
 Shuler, C.F., Halpern, D.E., Guo,Y., and Sank, A.C.(1992).Medial edge 
epithelium fate traced by cell lineage analysis during epithelial- 
mesenchymal transformation in vivo. Dev.Biol. 154, 318–330. 
 Singh GD, Johnston J, Ma W, Lozanoff S. (1998). Cleft palate formation in 
fetal Br mice with midfacial retrusion: tenascin, fibronectin, laminin, and 
type IV collagen immunolocalization. Cleft Palate Craniofac J, 35:65–76. 
 Smith TM, Wang X, Zhang W, Kulyk W, Nazarali AJ. (2009). Hoxa2 plays a 
direct role in murine palate development. Dev Dynam, 238:2364-2373. 
 Stapleton, P., Weith, A., Urbánek, P., Kozmik, Z. and Busslinger, M. 
(1993). Chromosomal localization of seven PAX genes and cloning of a 
novel family member, PAX-9. Nat. Genet. 3, 292-298. 
 Sulik KK. Dr. Beverly R.  (1990). Rollnick memorial lecture. Normal and 
abnormal craniofacial embryogenesis. Birth Defects Orig Artic Ser, 26:1–
18. 
 Sun, D., Vanderburg, C. R., Odierana, G. S. and Hay, E. D. (1998). 
TGFbeta3 Promotes Transformation of Chicken Palate Medial Edge 
Epithelium to Mesenchyme in Vitro. Development 125, 95-105. 
 Tara M.Smith, Scott Lozanoff, Paul P. Iyyanar and AdilJ.Nazarali. (2013). 
Molecular signalling along the anterior-posterior axis of early palate 
development. Frontiers in Physiology.; Craniofacial Biology. Volume 3, 
Article 488. 
 Thornton CA, Wymer JP, Simmons Z, McClain C, Moxley RT. (1997). 
Expansion of the myotonic dystrophy CTG repeat reduces expression of 
the flanking DMAHP gene. Nat Genet, 16:407±409. 
 Tyler MS, Pratt RM. (1980). Effect of epidermal growth factor on 
secondary palatal epithelium in vitro: tissue isolation and recombination 
studies. J Embryol Exp Morphol, 58: 93–106. 
94 
 
 Vaziri Sani F, Hallberg K, Harfe BD, Mc-Mahon AP, Linde A, Gritli-Linde A. 
(2005). Fate-mapping of the epithelial seam during palatal fusion rules 
out epithelial-mesenchymal transformation. Dev Biol, 285:490–495. 
 Wallis DE, Roessler E, Hehr.  (1999): Mutations in the homeodomain of 
the human SIX3 gene cause holoprosencephaly. Nat Genet, 22: 196–198. 
 Walsh CA. (1999). Genetic malformations of the human cerebral cortex. 
Neuron, 23:19±29. 
 Wellik, D.M., Hawkes, P.J., Capecchi, M.R. (2002). Hox11 paralogous 
genes are essential for metanephric kidney induction. Genes Dev. 16, 
1423–1432. 
 Welsh, I. C. and O’Brien, T. P. (2009). Signaling integration in the rugae 
growth zone directs sequential SHH signaling center formation during 
the rostral outgrowth of the palate. Dev. Biol. 336, 53-67. 
 Welsh, I. C., Hagge-Greenberg, A. and O’Brien, T. P. (2007). A Dosage-
Dependent Role for Spry2 in Growth and Patterning during Palate 
Development. Mech. Develop. 124, 746-761. 
 Winchester CL, Ferrier RK, Sermoni A, Clark BJ, Johnson KJ.  (1999). 
Characterization of the expression of DMPK and SIX5 in the human eye 
and implications for pathogenesis in myotonic dystrophy. Hum Mol 
Genet, 8:481±492. 
 Xiaoyan Lv, Zhaomin Mao, Zhongshi Lyu, Pengzong Zhang, Alan Zhan, 
Jian Wang, Hui Yang, Mi Li, Honglian Wang, QianYa Wan, Hongyuan Wei, 
Ming Wang, Nian Wang, Xun Li, Yi Liu, Hui Zhao and Qin Zhou. (2014). 
MiR181c promotes apoptosis and suppresses proliferation of 
metanephric mesenchyme cells by targeting Six2 in vitro. Cell Biochem 
Funct, 32: 571-579. 
95 
 
 Xiong, W., He, F., Morikawa, Y., Yu, X., Zhang, Z., Lan, Y., Jiang, R., 
Cserjesi, P. and Chen, Y. (2009). Hand2 is required in the epithelium for 
palatogenesis in mice. Dev. Biol. 330, 131-141. 
 Yu, L., Gu, S., Alappat, S., Song, Y., Yan, M., Zhang, X., Zhang, G., Jiang, Y., 
Zhang, Z., Zhang, Y. et al. (2005). Shox2-deficient mice exhibit a rare type 
of incomplete clefting of the secondary palate. Development 132, 4397-
4406. 
 Zhang, Y., Zhao, X., Hu, Y., St Amand, T., Zhang, M., Ramamurthy, R., Qiu, 
M. And Chen, Y. (1999). Msx1 is required for the induction of Patched by 
Sonic hedgehog in the mammalian tooth germ. Dev. Dyn. 215, 45-53. 
 Zhang, Z., Song, Y., Zhao, X., Zhang, X., Fermin, C. and Chen, Y. (2002). 
Rescue of cleft palate in Msx1-deficient mice by transgenic Bmp4 reveals 
a network of BMP and Shh signaling in the regulation of mammalian 
palatogenesis. Development 129, 4135- 4146. 
 
 
 
 
 
 
 
 
 
96 
 
11. APPENDIX 
In vivo cell counting analysis 
Table 1: N of 1 
                                      Dapi positive cells (total cell number) 
       Anterior           Medial        Posterior  
 Oral  Nasal  Oral  Nasal  Oral  Nasal  
Wild type  134 148 320 144 256 283 
Hoxa2 null 144 170 182 206 245 266 
                                      Ki-67 positive cells 
Wild type  49 72 108 154 157 261 
Hoxa2 null 90 120 124 173 170 228 
                                      Six2/Ki-67 double positive cells 
Wild type  22 39 56 92 130 140 
Hoxa2 null 34 43 72 105 127 91 
                                      Six2 positive cells 
Wild type  92 84 256 159 182 127 
Hoxa2 null 138 109 179 182 232 205 
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   Table 2: N of 2 
                                      Dapi positive cells (total cell number) 
       Anterior          Medial         Posterior  
 Oral  Nasal  Oral  Nasal  Oral  Nasal  
Wild type  223 262 247 250 254 291 
Hoxa2 null 236 227 202 181 247 277 
                                      Ki-67 positive cells 
Wild type  74 90 75 100 63 97 
Hoxa2 null 107 126 98 154 168 193 
                                      Six2/Ki-67 double positive cells 
Wild type  53 50 54 65 56 59 
Hoxa2 null 74 77 77 112 125 107 
                                      Six2 positive cells 
Wild type  170 145 180 154 189 171 
Hoxa2 null 200 170 196 168 241 236 
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Table 3: N of 3 
                                      Dapi positive cells (total cell number) 
       Anterior           Medial        Posterior  
 Oral  Nasal  Oral  Nasal  Oral  Nasal  
Wild type  164 184 172 194 232 291 
Hoxa2 null 142 147 193 240 250 211 
                                      Ki-67 positive cells 
Wild type  82 95 95 101 102 118 
Hoxa2 null 83 92 82 140 120 136 
                                      Six2/Ki-67 double positive cells 
Wild type  34 42 77 78 55 70 
Hoxa2 null 35 26 65 87 82 104 
                                      Six2 positive cells 
Wild type  96 82 129 102 145 112 
Hoxa2 null 121 114 181 179 244 198 
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Table 4: N of 4 
                                      Dapi positive cells (total cell number) 
       Anterior           Medial        Posterior  
 Oral  Nasal  Oral  Nasal  Oral  Nasal  
Wild type  220 247 193 240 203 200 
Hoxa2 null 88 123 145 160 225 208 
                                      Ki-67 positive cells 
Wild type  41 90 128 137 81 91 
Hoxa2 null 59 66 72 111 124 121 
                                      Six2/Ki-67 double positive cells 
Wild type  46 44 104 95 51 58 
Hoxa2 null 47 46 68 95 95 90 
                                      Six2 positive cells 
Wild type  165 148 144 135 155 148 
Hoxa2 null 83 94 139 132 220 178 
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Table 5: Ki-67 positive cells as a percentage of Dapi positive (total) cells in the 
whole palate. 
N             Anterior              Medial            Posterior  
 Wild type  Hoxa2 null Wild type  Hoxa2 null Wild type Hoxa2 null 
1 42.91% 66.88% 38.78% 76.55% 47.20% 93.54% 
2 33.81% 50.32% 35.21% 65.80% 43.89% 68.89% 
3 43.25% 60.55% 53.55% 51.27% 42.45% 70.53% 
4 28.05% 59.24% 37.23% 60.00% 58.56% 72.65% 
 
 
Table 6: Ki-67 positive cells as a percentage of Dapi positive (total) cells in the 
Wild type palate; Oral vs. Nasal. 
N             Anterior              Medial            Posterior  
 Oral  Nasal Oral   Nasal Oral  Nasal  
1 35.57% 48.65% 40.37% 52.49% 61.33% 76.87% 
2 33.18% 34.35% 30.36% 40.00% 44.98% 58.99% 
3 46.64% 51.63% 47.22% 52.06% 43.97% 63.45% 
4 18.64% 36.44% 45.32% 54.34% 39.90% 49.19% 
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Table 7: Ki-67 positive cells as a percentage of Dapi positive (total)  cells in 
the Hoxa2 null palate; Oral vs. Nasal. 
N             Anterior              Medial            Posterior  
 Oral  Nasal Oral   Nasal Oral  Nasal  
1 43.78% 70.59% 63.13% 83.98% 69.39% 85.71% 
2 45.34% 55.10% 48.51% 75.67% 68.02% 88.78% 
3 58.45% 62.59% 42.49% 58.33% 48.00% 71.09% 
4 47.98% 53.66% 49.66% 69.38% 55.10% 72.02% 
 
 
Table 8: Six2 positive cells as a percentage of Dapi positive (total)  cells in the 
whole palate. 
N             Anterior              Medial            Posterior  
 Wild type  Hoxa2 null Wild type  Hoxa2 null Wild type Hoxa2 null 
1 62.77% 76.23% 73.58% 81.45% 57.33% 96.28% 
2 64.99% 79.91% 67.20% 89.49% 76.06% 98.87% 
3 51.15% 81.31% 63.11% 87.25% 69.67% 95.88% 
4 67.02% 74.89% 67.55% 84.61% 78.79% 78.99% 
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Table 9: Six2/Ki-67 double positive cells as a percentage of Six2 positive cells 
in the whole palate. 
N             Anterior              Medial            Posterior  
 Wild type  Hoxa2 null Wild type  Hoxa2 null Wild type Hoxa2 null 
1 27.79% 46.41% 35.66% 49.03% 52.51% 67.42% 
2 32.70% 40.81% 35.63% 51.92% 52.32% 61.99% 
3 42.70% 25.98% 48.98% 42.22% 48.64% 64.76% 
4 28.75% 52.54% 42.64% 60.15% 47.35% 46.48% 
 
 
Table 10: Six2/Ki-67 double positive cells as a percentage of Six2 positive cells 
in the Wild type palate; Oral vs Nasal. 
N             Anterior              Medial            Posterior  
 Oral  Nasal Oral   Nasal Oral  Nasal  
1 23.91% 31.24% 21.88% 57.86% 63.21% 71.41% 
2 31.18% 34.48% 30.00% 42.21% 29.63% 34.50% 
3 36.96% 27.86% 35.91% 44.70% 37.93% 62.50% 
4 27.88% 34.13% 43.22% 42.78% 32.90% 39.19% 
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Table 11: Six2/Ki-67 double positive cells as a percentage of Six2 positive cells 
in the Hoxa2 null palate; Oral vs Nasal. 
N             Anterior              Medial            Posterior  
 Oral  Nasal Oral   Nasal Oral  Nasal  
1 38.41% 39.45% 40.22% 57.69% 54.74% 61.75% 
2 37.00% 45.29% 39.29% 61.54% 51.87% 64.55% 
3 28.93% 41.42% 47.32% 48.60% 45.90% 69.95% 
4 56.63% 39.79% 48.92% 65.78% 43.18% 50.56% 
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Absolute quantitative expression of palatal Six2 mRNA by droplet digital PCR 
 
Figure 1: Six2 mRNA expression by ddPCR. Absolute quantitative expression 
of Six2 mRNA during murine palatogenesis in wild type and Hoxa2 null mice. 
In the wild type mice, Six2 mRNA expression is comparably high at E12.5 and 
E13.5 and reduces at E14.5 before decreasing further at E15.5. In the Hoxa2 
null mice, expression is enhanced across all stages of palatogenesis. In the 
absence of Hoxa2, Six2 mRNA is high at E12.5 and increases to a peak level at 
E13.5. This expression dramatically reduces at E14.5 before decreasing further 
at E15.5. Bars represent mean ± SEM, n=5, *p<0.05, **p<0.01. 
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Figure 2. Sample of the Genotyping Results of Hoxa2 Transgenic Mice. A gel 
(using Red Safe) of the PCR analysis used in the genotyping of Hoxa2 transgenic 
mice. The presence of a band with the wild-type primers only (A) confirms that 
the animal is wild-type. If a band is present only with the neomycin primers (C) 
this confirms the embryo is Hoxa2 null. Presence of both bands indicates that 
the animal is a heterozygote (B). 
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Table 12: Primers used for qPCR analysis of Msx1, Bmp4, Barx1 and Ptx1. 
 Forward primer Reverse primer 
Msx1 CTCGGTGTCAAAGTGGAGG GCTGAAGGGCAGGAGTGAA 
Barx1 ATTGCGAGGACTGAGCGT GACACCTGGGATTGGCTTC 
Bmp4 AGGAAGGAGTAGATGTGAGAG AGGGACGGAGACCAGATAC 
Ptx1 ACCCGAGCCTTAGAAACC GACCTGTTGGGGACAAGA 
Six2 GCCAAGGAAAGGGAGAACAGC GCGTCTTCTCATCCTCGGAAC 
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Figure 3: An agarose gel showing the integrity of the primers that were used 
for PCR genotyping analysis. All bands were single with no formation of 
primer- dimmers. 
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Table of Reagent catalogue numbers 
Reagent name Company name Calatogue number 
Six2 Taqman probes Applied Biosystems Mm03003557_S1 
Six2 antibody Protein Tech 11562-A-P 
Msx1 Sybr green primers Invitrogen 10336022 
Bmp4 Sybr green primers Invitrogen 10336022 
Barx1 Sybr green primers Invitrogen 10336022 
Ptx1 Sybr green primers Invitrogen 10336022 
Lipofectamine 3000 Invitrogen 1559381 
Six2 silencer select siRNA Life Technologies 4390771 
E-cadherin antibody Sigma U 3254 
Ki-67 antibody Affymetrix e-bioscience 13-5698-82 
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